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ABSTRACT 
TUMOR-DERIVED EXOSOMES DRIVE IMMUNOSUPPRESSIVE MACROPHAGES IN 
A PRE-METASTATIC NICHE THROUGH NF-KΒ DEPENDENT GLYCOLYTIC 
METABOLIC REPROGRAMMING 
Samantha M. Morrissey 
June 16, 2020 
The formation of a pre-metastatic niche is a fundamental requirement for primary tumor 
metastasis. One of the defining characteristics of a pre-metastatic niche is infiltration of 
immunosuppressive macrophages. However, how these macrophages acquire their 
immunosuppressive phenotype remains largely unexplored. Here, we demonstrate that 
tumor-derived exosomes (TDE) polarize macrophages towards an immunosuppressive 
phenotype characterized by increased PD-L1 expression through NF-kB-dependent 
metabolic reprogramming in mice and humans. While NF-κB has previously been shown 
to act as a direct transcription factor for PD-L1, we report a novel mechanism where 
TDE-induced NF-κB activation drives PD-L1 expression by augmenting the glycolytic 
capacity of macrophages through two separate pathways. First, NF-κB increases 
glucose uptake into macrophages via a HIF-1α/GLUT-1-dependent mechanism. 
Secondly, elevated NOS2-dependent nitric oxide inhibits mitochondrial oxidative 
phosphorylation resulting in an increased conversion of pyruvate to lactate. Lactate then 
feeds back on NF-κB further increasing PD-L1 expression. Analysis of metastasis 
vi 
negative draining lymph nodes of non-small cell lung cancer patients revealed that 
macrophage PD-L1 expression positively correlates with expression levels of GLUT-1 
and exosomal release genes YKT6 and TSG101 from primary tumors. Collectively, our 
study provides a novel mechanism by which macrophages within a pre-metastatic niche 
acquire their immunosuppressive phenotype and identifies an important link between 
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1. OVERVIEW
1.1 Overview of Innate and Adaptive Immunity 
The human immune system has developed as a result of an amalgamation of 
traits over hundreds of millions of years from both vertebrate and non-vertebrate 
animals1, 2. These traits consist of a variety of different cellular responses that protect the 
host from invading pathogens. Over time, this conglomerate has been stratified into the 
three main branches of immunological defense: physical barriers, innate immunity, and 
adaptive immunity3. Each facet of the human immune system has distinctive properties 
that make up its respective defense mechanism. 
The first and largest barrier to infection is the skin1. It along with various mucus 
membranes constitute the physical barriers separating host from pathogen. Keratinized 
skin cells from a tough outer layer that can only be breached by physical damage 
resulting from wounds, burns, and surgical procedures. The mucus membranes that line 
the respiratory, gastrointestinal, and urogenital tracts are designed with specialized fluid 
layers consisting of glycoproteins, proteoglycans, and enzymes that trap and expel 
pathogens from the body1. Should the various physical barriers become breached, the 
second line of defense, the innate immune system is mobilized into action.  
Once a pathogen, like bacteria, has surpassed the external defenses and 
entered the body, it is first recognized by a variety of effector mechanisms known as the 
innate immune system1.  The hallmark sign of activation of the innate immune system is 
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inflammation. Inflammation is characterized by warmth, pain, redness, and swelling1. 
Mechanistically, inflammation results from activation of the resident effector cells called 
macrophages. Macrophages are the mature form of circulating monocytes that localize 
to particular areas of the body that are most susceptible to invading pathogens. 
Deposition of small proteins, called complement, on the surface of invading pathogens 
mark and attract macrophages to promote clearance of the pathogen through a process 
called phagocytosis or “cellular eating”4. The surface of macrophages is lined with 
specialized receptors, toll-like-receptors, (TLRs) that are specifically designed to 
recognize different types of microbial products.  Activation of macrophages through TLR 
signaling results in transcription of a variety of inflammatory cytokines that amplify the 
immune response. These mediators include interleukin-6 (IL-6), interleukin-1β (IL-1β), 
and tumor-necrosis factor-α (TNFα) and often are responsible for driving the clinical 
symptoms associated with infection: fever, increased C-reactive protein, and 
neutrophilia1. However, while this response is rapid and robust, it is often not enough to 
limit the course of infection and a secondary, more specialized, system is needed to 
ultimately clear the pathogen.  
The final arm of the human immune system is the adaptive immune system and it 
is responsible for immunological memory, the premise upon which vaccination is built1. 
The two main mediators of adaptive immunity are B cells and T cells3. Any molecule or 
macromolecule that is capable of being bound by a T-cell receptor (TCR) or B-cell 
receptor (BCR) is known as an antigen. The particular part of antigen that is recognized 
by the TCR or BCR is an epitope. T cell and B cell receptors consist of two separate 
parts, the constant region and the variable region. The variable region contains the site 
that binds specific pathogen associated epitopes. The ability for TCRs and BCRs to bind 
to the limitless number of pathogen-associated epitopes is conferred by a process 
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known as somatic recombination. Within this process, numerous combinations of gene 
segments are rearranged allowing for a pool of cells with different receptor specificities, 
called clones. Elimination of clones that are specific for host cell epitopes is achieved 
through a process known as clonal selection5. T-cell clones that recognize antigen 
complexed with the self-glycoprotein called major histocompatibility complex (MHC) are 
positively selected for in the thymus. CD8+ T cells recognize antigen presented via MHC 
Class I while CD4+ T cells recognize MHC Class II. Following positive selection, clones 
that recognize self-peptides in the context of MHC I and MHC II are eliminated via 
apoptosis or programmed cell death. Errors in this process are considered to be one 
potential mechanism by which autoimmune disease develops6. B cells go through a 
similar process as T cells for selection. However, upon pathogen infection, they have an 
additional mechanism for diversification, somatic hypermutation. Introduction of 
nucleotide substitutions in the heavy and light chains of B cell receptors produces 
antibodies that bind pathogens more tightly allowing for more specified pathogen 
clearance. A certain subset of these specific antibody producing cells will go on to 
become plasma cells.  
In addition to phagocytosis and production of cytokines, another role for 
macrophages in innate immunity is presentation of antigen to T cells thus classifying 
them as antigen-presenting cells (APCs)1. Macrophages and other APCs, such dendritic 
cells, load antigens into their MHCs at the site of infection and travel to the local 
secondary lymphoid structure, often the draining lymph node, where they present 
antigen to the resident T cells. A small number of T cells with TCRs specific to the 
loaded antigen are activated and clonal expansion of these cells results in in pool of 
effector T cells. Activated cytotoxic CD8+ T cells hone to the site of infection via 
particular cytokine gradients and kill the invading pathogen. Conversely CD4+ T cells, or 
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helper T cells, in the lymph node interact via a surface receptor called CD40-ligand 
(CD40L) with antigen specific B cells, releasing the necessary cytokines (IL-4, IL-5, IL-6) 
for B cell proliferation and differentiation1.  
Overall, the process of innate and adaptive immune activation takes roughly two 
weeks which is the normal duration of the common cold7. However, reinfection with the 
same pathogen in the future will result in a robust reactivation of specific memory T and 
B cells from the primary infection allowing for rapid identification and clearance of the 
pathogen8. It is this mechanism of long-lasting immunity that has allowed for successful 
eradication of diseases like smallpox from the population9.  
1.2 Immune landscape of cancer 
The immune system has developed over hundreds of millions of years to fight 
foreign invading pathogens like fungi, bacteria, and viruses2. However, not all disease 
causing pathogens are extrinsic to the host. One disease in particular that has 
developed synonymously within the host is cancer. Unlike foreign pathogens that look 
very different from self in the eyes of the immune system, cancerous cells are native 
cells that proliferate uncontrollably as a result of genetic mutation causing disruption to 
normal physiology and ultimately disease1.  Because cancer has co-evolved with the 
immune system, it has effectively developed a variety of mechanisms that mitigate the 
majority of attacks mounted by both the innate and adaptive immune systems.  
The interplay between the immune system and the development of cancerous 
neoplasms is called immunosurveillance10. It was first put forth by Dr. Paul Ehrlich in 
1909, that the immune system must be responsible for suppressing growth of 
carcinomas or else they would occur at a far greater rate. Technological advancements 
over past two decades in particular have allowed for further investigation into this 
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dynamic and complex relationship. From these studies, the “Three E Paradigm” of 
cancer immunoediting was born10. This hypothesis is based on the notion of three 
phases of tumor progression with regards to immunologic surveillance- elimination, 
equilibrium, and escape.  
The first phase of immunosurveillance, elimination, harkens back to Ehrlich’s 
original concept of immune mediated oncological suppression. The human body is 
exposed to hundreds of carcinogens on almost a daily basis that are capable of causing 
genetic mutation11. However, due to the process of elimination, the majority of mutated 
cells are cleared prior to tumor formation12. In the elimination phase, both innate and 
adaptive immune cells are mobilized to identify potentially cancer cells. These “danger 
signals” which can be readily recognized by the innate immune system include 
increased production of uric acid, and generation of proinflammatory responses from 
expression of TLR ligands and heat shock proteins12. Studies using mice deficient in the 
recombination activating gene (RAG) which is responsible for TCR and BCR 
diversification, saw dramatic increases in tumor burden as compared to original wild type 
hosts pointing towards a regulatory role for B cells and T cells in cancer progression12.  
While engagement of the host immune system with tumor cells has been shown 
to limit the emergence of fully developed neoplasms, it is also responsible for shaping 
the tumor’s immunological phenotype. Namely, within the elimination phase, tumor cells 
that are susceptible to immunoregulation are selected against, while those that are 
resistant to immunological elimination are positively selected for. This selection pressure 
is what brings the tumor cells to the second phase of immunoediting-equilibrium10, 12. 
While a significant portion of tumor cells are culled out by the immune system, those that 
remain pose a significant threat due to their inherent resistance to immune targeting. 
These cells often result from genetic instability within the primary tumor allowing for 
stochastic generation of clones that display increased resilience in the face of 
6 
 
immunological selection pressure1. Clinically, the idea of cancer equilibrium becomes 
apparent in case of transmission of cancer from donor to recipient in organ transplant13. 
Grossly, the organ appears cancer-free, however, following transmission into an 
immunocompromised recipient, the dormant cancer cells that were held in check by the 
immunocompetent donor overpower the fledgling immune system of transplant recipient 
leading to the last stage of immunoediting- escape14.  
Tumor escape is defined as uncontrolled proliferation and progression 
unrestrained by immune pressure10. During the escape phase tumors become clinically 
apparent. It is thought that both genetic and epigenetic modifications of the tumor cells 
are responsible for conferring mechanisms that circumvent both the innate and adaptive 
branches of the immune system. Therefore, the focus in the field over the past 30 years 
or so has been to elucidate the types of resistance mechanisms the tumor cells generate 
in order to develop new therapeutics against them15. This pursuit has birthed an entire 
new arm of immunological research called immunotherapy16.  
 
1.3 Immunotherapy and the forefront of the cancer crusade  
 
The concept of immunotherapy, or using the immune system as a therapeutic 
against cancer, was first put forth by Dr. William B. Coley beginning in 189117. He 
believed that administration of bacterial toxins into patients with non-resectable tumors 
would galvanize the immune system into orchestrating increased surveillance and 
elimination. During forty years of practice, Coley treated over 1000 bone and soft-tissue 
sarcoma patients with his toxins achieving varying successful outcomes18. Unfortunately, 
widespread criticism in the field combined with the advent of radiotherapy and 
chemotherapy caused the use of Coley’s Toxins to fall out of favor.  However, Coley had 
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started the burgeoning field of immunotherapy that a century later would be the forefront 
of the immunological crusade against cancer.  
Up until recently the three main pillars of cancer treatment were surgery, 
radiation, and chemotherapy19. However, major advances in the field of immunotherapy, 
particularly with immune checkpoint inhibitors and adoptive cell therapies, are changing 
the norm. In 2018, James Allison and Tasuku Honjo were awarded the Nobel Prize in 
Physiology or Medicine for their discovery and use of immune checkpoint molecules, 
cytotoxic T-lymphocyte associated protein-4 (CTLA-4) and Programmed Death-1 (PD-1), 
respectively for cancer immunotherapy20. These proteins each expressed on the surface 
of T cells are mechanisms to control errant T cell responses following 
infection/activation. However, cancer cells coopted this system to protect themselves, 
causing blunting of the infiltrating cytotoxic T cells responses in tumors21. The 
development and utilization of blocking antibodies that interfere with this process have 
demonstrated remarkable efficacy in the clinic22. To date, anti-CTLA-4 and anti-PD-1 
monoclonal antibody treatments have been FDA approved as first line treatments for 
melanoma and non-small lung cancer in addition to receiving approval as adjunct 
therapies for numerous types of cancer including kidney, liver, bladder, esophageal, 
head and neck squamous cell, colorectal and uterine cancer23.  Immunotherapy has 
brought the 5-year survival rate for melanomas patients up to an astonishing 98%24. 
However, that figure dramatically drops to only 23% for metastatic melanoma. Therefore, 
gaining a better understanding of the mechanisms of primary tumor metastasis and 
immunotherapy resistance is of paramount importance to increase overall survival rates 
of patients with metastatic cancer.  
1.4 Scope of Dissertation Study 
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The work herein deals with two mechanisms of primary tumor metastasis, pre-
metastatic niche formation and immunometabolism. The first set of studies, described in 
Chapter 2, detail the role small nanoparticles called exosomes released from the primary 
tumor play in priming a distant tissue for tumor metastasis. Specifically, this work 
provides insight into exosomes’ influence on the phenotype and functionality of 
macrophages within a pre-metastatic niche. The second set of studies, presented in 
Chapter 3, focuses on the mechanism by which exosomes polarize tissue resident 
macrophages towards the immunosuppressive phenotype detailed in Chapter 2. These 
studies reveal a novel connection between exosomes, glycolytic metabolism, and lactate 
that drives increased expression of the immune checkpoint molecule, programmed 
death ligand- 1 (PD-L1) on macrophages in a pre-metastatic niche. Overall, this study 
aims to better characterize mechanisms of metastasis in effort to identify novel targets to 
help increase the efficacy of immunotherapies and improve outcomes for patients with 
metastatic cancer.   
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2. TUMOR DERIVED EXOSOMES DRIVE PD-L1 EXPRESSION IN TISSUE
RESIDENT MACROPHAGES 
2.1 INTRODUCTION 
2.1.1 Non-small cell lung cancer 
Lung cancer, particularly non-small cell lung cancer (NSCLC), is the most 
common form of cancer worldwide in men and the third most common in women 25. 
NSCLC is a group of cancers that include the adenocarcinoma, squamous cell, and 
large cell subtypes26. Adenocarcinoma lesions are often found on the outer lobes of the 
lung and are comprised of mutated mucus secreting cells. Squamous cell carcinoma 
lesions, as their name implies, start in the squamous epithelial cells that line the lung 
bronchi. These tumors are often found more medially in the lung. Both adenocarcinoma 
and squamous cell carcinoma are associated with a history of smoking27. Large cell 
carcinoma is less common than the other two and can be found in any part of the lung. It 
often grows faster and larger than the other two subtypes making it more difficult to treat. 
Because the lung is a highly perfused organ, it is one of the most common sites 
of metastasis for a variety of primary cancer types including bladder, breast, colon, and 
kidney among others28. The symptoms of metastatic cancer to the lung are similar to that 
of primary lung cancer and include persistent cough, hemoptysis, dyspnea, and sudden 
weight loss27.  Metastatic lung cancer occurs in 20% to 54% of all solid tumor cancer 
patients depending on the original tumor type 29. Despite advances in current therapies, 
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metastasis remains a major challenge with poor five-year survival outcomes for a 
majority of patients 30. The FDA has approved the use of pembrolizumab (anti-PD-1) in 
patients with metastatic NSCLC patients whose primary tumors had ≥50% expression of 
PD-L1 in addition to patients that have Stage III non-resectable NSCLC31. Combination 
treatment with immunotherapy agents like Pembrolizumab have increased the median 
progression free survival rates for patients with later stages cancers to approximately 8.8 
months, almost a 50% improvement over sole treatment with platinum-based 
chemotherapy32. However, only roughly 20% of patients achieve a sustained response 
to the therapy33. Therefore, it is critical to delineate which factors are driving 
immunotherapy resistance.  
2.1.2 Pre-metastatic niche formation 
The theory behind primary tumor metastasis began in 1889 with Stephen Paget’s 
Seed and Soil hypothesis which likens the ability of tumors to metastasize to seeds 
falling on congenial soil34. He believed that metastasis was not a random phenomenon 
solely dependent on the anatomical structure of the vascular system and that certain 
factors had to prime the secondary tissue to permit tumor cells to grow. The process 
through with a secondary tissue undergoes remodeling for the purpose of preparing for 
tumor cell implantation is pre-metastatic niche formation. Accumulating evidence 
suggests that cancer metastasis is a temporal and spatial process that starts with the 
formation of a favorable local environment within a distant tissue35.  
One of the first events that is necessary for tumor metastasis is the epithelial to 
mesenchymal transition (EMT) of primary tumor cells36. Within this process, tumor cells 
downregulate surface epithelial markers and upregulate mesenchymal markers that 
confer a more stem-like, migratory phenotype. Following this transformation, the next 
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rate-limiting step of metastasis is intravasation of the tumor cells into circulation. 
Intravasation is a low-fidelity process with only 0.01% of intravasating tumor cells 
successfully forming metastatic lesions36. Once through the vessel wall and into the 
bloodstream, it is thought that circulating tumor cells associate with platelets as an 
additive layer of protection from immune surveillance37. For the circulating tumor cells 
that survive the inhospitable environment of circulation, successful extravasation, 
modulation of the endothelial barrier and transendothelial migration are necessary for 
tissue invasion and colonization38. These processes are thought to be mediated by a 
variety of intrinsic tumor associated factors as well as extrinsic factors secreted by 
endothelial cells, platelets, and other infiltrating immune subtypes.     
While primary tumor cells are undergoing EMT, intravasation and extravasation, 
a series of molecular and cellular changes are happening in parallel to secondary 
tissues to create a pre-metastatic niche. There are six enabling characteristics of a pre-
metastatic niche that prepare and permit circulating tumor cells to engraft and grow. 
These characteristics include: inflammation, angiogenesis/vascular permeability, 
lymphangiogenesis, organotropism, reprogramming, and immunosuppression35.  
2.1.3 Immunosuppressive cell types within a pre-metastatic niche 
One of the defining characteristics of a primary tumor and its subsequent 
metastatic niche is immunosuppression. Elimination of localized immune responses is 
necessary and critical for tumor growth. There are a variety of factors that contribute to 
the immunosuppressive phenotype including decreased oxygen saturation, 
accumulation of immune dampening metabolites, and infiltration of regulatory immune 
cells39. Under normal physiological conditions, regulatory immune cells exist to limit and 
control immune cell activation during host/pathogen responses in order to prevent the 
12 
development of autoimmunity following resolution of the infection40. However, primary 
tumors hijack this system and release chemokines and cytokines as a defensive strategy 
to cause abnormal accumulation of immunosuppressive cells within the tissue. The four 
main classes of regulatory/suppressive immune cells are myeloid derived suppressor 
cells (MDSCs), Tregulatory cells (Tregs), tumor associated neutrophils (TAN) and tumor 
associated macrophages (TAMs)35, 41.  These classes of cells have been found around 
the invasive margin of highly fibrotic lesions like pancreatic ductal adenocarcinoma 
tumors and are speculated to prevent infiltration of cytotoxic lymphocytes resulting in 
what is called an infiltrated-excluded tumor immune microenvironment (TIME)42. In other 
types of TIME, such as the infiltrated-inflamed, the immune regulatory cells along with 
the cytotoxic lymphocytes highly penetrate into the core of the tumor42. Increased 
expression of immune checkpoint molecules, PD-1 on lymphocytes and PD-L1 on tumor 
cells, often still construes an immunosuppressive phenotype despite the marked influx of 
immune cells.  
While attention has been paid to the other types of immune regulatory cells within 
the pre-metastatic niche, the most notable and well characterized is the TAM. TAMs are 
considered to be a subset of M2-like polarized macrophages that can be identified by 
increases in Arginase-1 expression, IL-10 production, and mitochondria dependent 
oxidative phosphorylation43. Functionally, they are poor antigen presenting cells, have 
decreased phagocytic capabilities, and produce lower levels of nitric oxide43. Multiple 
murine models of cancer have shown the presence of TAMs, particularly yolk sac 
derived TAMs, increase the proliferative capacity of tumor cells42. Conversely, depletion 
of macrophages in both breast and colon cancer models significantly decreased the 
number of metastatic nodules indicating a strong role for macrophages in promoting 
tumor metastasis 44, 45. Interestingly, in terms of immune checkpoint blockade therapy, it 
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has been shown that PD-L1 expression on antigen presenting cells, like macrophages, 
is necessary for successful treatment with both anti-PD-1 and anti-PD-L1 monoclonal 
antibodies46. These results suggest that immunosuppressive macrophages might play a 
greater role in restraining T-cell activation than previously considered. Therefore, it is 
important to determine what factors drive PD-L1 expression on macrophages in the 
context of cancer.  
2.1.4 Exosomes 
Exosomes are small nanoparticles, 30-150 nm in diameter, that are released via 
exocytosis from the surface of both normal and tumor cells alike. Specifically, exosomes 
arise from the inward budding of vesicles in the late endosome to form a multivesicular 
body (MVB)47. Fusion of the MVB with the plasma membrane releases the exosomes 
extracellularly. Numerous proteins are involved in this process including RAB27, YKT6, 
and TSG10147. The cargo packaged into the exosomes prior to their release is very 
heterogenous including a wide assortment of RNA, DNA, proteins, microRNAs, 
metabolites, and other biologically active molecules derived from their parent cell. 
Interestingly, following release, exosomes often hone to particular highly vascularized 
tissues like the lung and liver based on their surface integrin profiles and the integrin 
profiles of their parental cell of origin 48. This organotrospism, or affinity of certain 
substances for particular tissues or organs, is believed to contribute to exosomes overall 
pro-tumorigenic phenotype35.  
Given their abundance and propensity to be found in bodily fluids, exosomes are 
being targeted clinically as potential biomarkers for cancer 49, 50. To date, exosomes 
have been isolated from a variety of bodily fluids including bile, blood, breast milk, urine, 
cerebrospinal fluid, and saliva51. The total concentration of exosomes isolated from the 
14 
 
plasma of head and neck squamous cell carcinoma patients positively correlates with 
active disease status and clinical stage suggesting a pathogenic nature 52. There has 
been an increasing focus on how TDE contribute to the complex intracellular 
communications within the tumor microenvironment53 . It has been shown that TDE and 
their associated miRNAs are capable of modulating tumor progression via secretion of 
pro-inflammatory cytokines, promotion of angiogenesis, TLR-3 driven neutrophil 
infiltration, and recruitment of myeloid-derived suppressor cells (MDSCs) 54, 55, 56, 57. 
Similarly, exosomal factors including miRNAs have been associated with promoting pre-
metastatic niche formation in various cancers 41. In ovarian cancer, which has one of 
highest rates of tumor metastasis within the abdominal cavity, TDE have been shown to 
induce pre-metastatic niche formation through IL-6 and Fas ligand mediated 
mechanisms of tumor cell escape50. Conversely, depletion of exosome secretion via 
genetic manipulation or pharmacological inhibition has been shown to decrease 
metastatic burden and increase overall survival in a variety of tumor-bearing mice58, 59, 60. 
Given the close association with tumor proliferation and growth, it is important to further 
elucidate the pro-tumoral characteristics of exosomes, particularly with regard to immune 
checkpoint therapy.  
2.1.5. Exosomes and PD-L1 
Accumulating evidence suggests that exosomes are a significant source of extra-
tumoral PD-L1 and may be one mechanism contributing to PD-1 Ab treatment 
resistance. Exosomes acquire their PD-L1 expression from endocytosis of parent cell 
surface PD-L1 60 61 62. Utilization of this characteristic has allowed for the isolation of 
exosomes from the supernatants of various tumor cell line cultures and human plasma 
through binding of surface PD-L1 to immobilized biotinylated PD-1 antibodies 62, 63, 64.  
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Different tumor cell lines or types of cancer have fluctuating amounts of PD-L1 
packaged into secreted exosomes. Metastatic melanoma cell lines were found to secrete 
exosomes with higher PD-L1 expression compared to primary cell lines 62. Exosomes 
extracted from the plasma of stage IV metastatic melanoma patients revealed increased 
exosomal PD-L1 expression compared to healthy donors 62. Furthermore, increased 
exosomal PD-L1 expression level has been found to positively correlate with increasing 
tumor size, higher disease activity, and overall clinical stage in a variety of cancers58, 62,
65, 66. Interestingly, soluble PD-L1 in the plasma of head and neck squamous cell 
carcinoma (HNSCC) patients did not correlate with clinical pathological parameters, 
further suggesting exosomal PD-L1 imparts a specific phenotype in cancer 65.  
As a secreted component from primary tumors, exosomes have been credited to 
possess a wide assortment of pre-metastatic niche enhancing characteristics 41. 
However, thus far, the majority of these pro-tumoral characteristics have been found to 
be mediated by intracellular mRNA, miRNA, and protein cargo contained within the 
exosomes 41, 67. Conversely, exosomal PD-L1 which is localized to the surface has been 
associated with tumor progression in a variety of cancers including melanoma, breast 
cancer, HNSCC, and glioblastoma 58, 62, 65, 66. Specifically, patients with metastatic 
melanoma had significantly higher levels of exosomal PD-L1 than healthy donors 62. In 
breast cancer, PD-L1/exosome co-localization increased with advancing tumor grade 
from Grade I/I-II to Grade II-III/III 58.  PD-L1 expression on exosomes correlated with 
glioblastoma tumor volumes and with clinical stage and level of nodal involvement in 
HNSCC 65, 66. In addition, exosome PD-L1 expression negatively correlated with 
postoperative survival time in pancreatic ductal adenocarcinoma patients 68. 
The high level of correlation between exosomal PD-L1 expression and advanced 
tumor staging suggests that PD-L1 on exosomes is responsible in some capacity for 
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augmenting tumor growth and metastasis. Previous studies in a variety of mouse models 
have shown that exogenous administration of tumor-derived exosomes increases 
metastatic potential and overall tumor burden of primary tumors 69, 70. However, only 
recently has this tumor promoting phenotype specifically been linked to exosomal PD-L1 
expression71. Treatment of PD-L1KO breast, prostate, and colorectal cell lines with PD-
L1 expressing exosomes restored tumor growth capabilities in a dose dependent 
manner 58 60. Multiple studies have shown that in vitro co-culture of PD-L1+/high exosomes 
with T cells results in inhibition of T cell activation 65 66 58 61.  
Labeling of exosomes from a variety of tumor models revealed that mainly 
phagocytic cells, over lymphocytes, uptake exosomes in their local microenvironment. 
CD14+ monocytes from glioblastoma patients compared to healthy controls 
demonstrated increased uptake of labeled exosomes from glioblastoma stem cells 72. 
Additionally, CD14+ cells resected directly from glioblastoma multiform patient samples 
showed increased PD-L1 expression compared to these in the peripheral blood from 
healthy donors. Similarly, mice receiving a single injection of labeled E0771 breast 
cancer derived exosomes showed the highest exosome signal in F4/80+CD11b+ 
macrophages in the lungs 70. However, the exact mechanisms behind the increased PD-
L1 expression and whether it contributes to pre-metastatic niche formation remains to be 
elucidated and therefore is the topic of this dissertation.  
2.1.6 Summary and Findings 
In this study, we investigated whether tumor-derived exosomes (TDE) contribute to 
macrophage mediated pre-metastatic niche formation and if so, by what signaling 
mechanism do TDE induce this polarization towards an immunosuppressive phenotype. 
We found that exogenous administration of TDE increased expression of metastasis-
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associated markers in naive mice and increased the metastatic burden in the lungs of 
subcutaneous tumor-bearing mice. TDE specifically drive de novo synthesis of PD-L1 in 
macrophages. The increased PD-L1 expression curtailed immune responses through 
inhibition of effector T cell functions in both mice and humans. We further reveled that 
PD-L1 expression on macrophages from metastasis negative draining lymph nodes of 
non-small cell lung cancer patients positively correlates with exosomal release genes 
YKT6 and TSG101 from primary tumors. Taken together, our findings support the idea 
that TDE drive primary tumor metastasis through polarization of tissue resident 
macrophages towards an immunosuppressive phenotype characterized by increased 
PD-L1 expression.  
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2.2 MATERIALS AND METHODS 
2.2.1 Mice 
C57BL/6, MyD88-/-, TLR2-/-, TLR4-/-, TLR6-/- TLR7-/-, OT-I and OT-II mice were purchased 
from commercially available vendors. TLR9-/- mice were purchased from Oriental Yeast 
Co. (Japan). LysM-cre;Raptorfl/fl and LysM-cre;Rictorfl/fl mice were generated by crossing 
LysMCre/wt with Raptorfl/fl or Rictorfl/fl mice both which were purchased from Jackson 
Laboratory (Bar Harbor, ME). Raptorfl/fl and Rictorfl/fl mice were used as controls. All 
animals were housed and treated in accordance with institutional guidelines and 
approved by the Institutional Animal Care and Use Committee at the University of 
Louisville, Louisville, KY.  
2.2.2 Cell culture and cell lines 
The authenticated human adenocarcinoma cell line A549, murine lung 
adenocarcinoma (LLC), colon carcinoma (MC38), and melanoma (B16-F10) cell lines 
were obtained from American Type Culture Collection (ATCC). The murine breast 
cancer cell line 4T-1 was kindly provided by Dr. Nejat Egilmez, Department of 
Microbiology and Immunology, University of Louisville. The control MLE-12 cell line 
was provided by Dr. Haribabu Bodduluri and the human HBEC cell line provided by 
Dr. Geoffrey Clark. All cell lines were cultured in DMEM supplemented with 10% FBS 
(Atlanta Biologicals), and 1% Penicillin-Streptomycin Solution (Corning). For exosome 
isolation studies, cells were cultured in appropriate medium with 10% exosome-free 
FBS (Thermo-Fisher Scientific, Waltham, MA). 
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RAB27KO 4T-1 cell line was generated using CRISPR/CAS9 technology. Briefly, cells 
were transfected with Rab27a sgRNA CRISPR All-in-One-Lentivirus set (Applied 
Biological Materials (abm), Vancouver, Canada) at a MOI of 10. Cells were also 
transfected with Scrambled sgRNA CRISPR/Cas9 All-in-One Lentivirus to serve as a 
control. Properly transfected cells were selected for using puromycin antibiotic 
selection. Genomic cleavage was detected using the CRISPR Genomic Cleavage 
Detection Kit and standard protocol (abm, cat. No. G932). The following sgRNA 
sequence was used: sg1Rab27 CCA CCT GCA GTT ATG GGA CA 
2.2.3 Exosome purification and characterization 
Supernatants were obtained from cancerous cell lines (LLC, 4T-1, MC38, B16-F10, 
and A549) and non-cancerous epithelial cell lines (MLE-12 and HBEC) grown to 80% 
confluence over a 48 hour period in the appropriate growth media. For in vivo 
exosome isolation, primary tumors were excised, mechanically separated and 
enzymatically digested (collagenase (5g/L), Hyaluronidase(0.4g/L), DNAse I 
(0.15g/L)) for 35 minutes with rotation at 37°C. Cells were then cultured in complete 
DMEM as specified for cell lines. Exosomes were prepared as previously described 73,
74. Briefly, the cell supernatants were spun once each at 2,000 x g and 10,000 x g.
The supernatant was decanted and then carefully layered on top of 8mL of 30% 
sucrose prior to beging spun at 100,000 x g for 90 minutes. The supernatant was 
removed and the sucrose fraction containing the exosomes was washed with PBS 
and spun again at 100,000 x g for 90 minutes. Exosomes were collected using 150ul 
of PBS. Exosomes were then run through qEV 35nm single use columns (Izon 
Biosciences, Boston, MA) for further purification. Samples were run on a NanoSight 
NS300 to confirm exosome isolation via size verification. The total exosomal protein 
concentrations were determined by using the BCA Protein Assay kit (Thermo Fisher 
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Scientific, Santa Clara, CA). Finally, an Exo-check Antibody Array (Systems 
Bioscience, Palo Alto CA) was used to confirm proper surface marker expression 
profile for exosomes.  
2.2.4 Isolation of Peritoneal Macrophages  
Peritoneal macrophages were harvested by peritoneal lavage as previously described 
75. Briefly, cold 3% FBS was injected into the peritoneal cavity and extracted after
gentle agitation. The peritoneal cell suspension was centrifuged at 1600 r.p.m. After 
centrifugation, cells were resuspended in complete RPMI-1640 supplemented with 
10% FBS (Atlanta Biologicals), and 1% Penicillin-Streptomycin Solution (Corning). 
Unless otherwise noted, cells were plated at a density of 5.0x105 cells/well in a 24 
well plate. Cells were incubated at 37°C for 2 hours to allow macrophages to adhere 
to the plate. Floating cells were removed by two subsequent washes with PBS. For 
cell sorting, peritoneal macrophages were stained with Fixable Viability Dye and 
F4/80/FITC antibody (Biolegend) at 4°C for 30 min in the dark. Samples were then 
washed and resuspended in MACS running buffer. The samples were sorted on a 
FACS Aria gated on singlets followed by live, F4/80+. Cells were immediately plated 
for use in subsequent experiments.  
2.2.5 In Vitro Peritoneal Macrophage Culture 
Peritoneal macrophages were treated with MLE-12 Exo or LLC exo (40μg/mL) for 16 
hours. After incubation, supernatant was removed and cells were washed briefly with 
PBS. Cells were harvested by adding 500μL Cell Stripper (Corn ing) and incubated for 
1 minute at 37°C. RPMI-1640 was added to quench the reaction and cells were gently 
removed by scraping. For NF-κB experiments, macrophages were pre-treated with 0.2 
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μg/mL BAY-11-7082 for 1 hour at 37°C. Cells were then washed with PBS and then 
treated with exosomal stimulation as normal. For the HMGB-1 studies, cells were 
stimulated with 10μg/mL recombinant murine HMGB-1 (Cat# 764006, Biolegend) for 16 
hours.   
2.2.6 Murine T cell proliferation assay  
Splenocytes from Ova-transgenic-I (OT-I) and Ova-transgenic-II (OT-II) mice were 
labeled with 5(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE cell trace, 
Thermo Fisher) at a concentration of 1 μM/mL according to manufac turer’s 
instructions. Briefly, CFSE labelled cells were co-cultured with macrophages pre-
treated with 40ug/mL exosomes (48 hours) at a 1:15 ratio. Macrophages were 
washed prior to T-cell addition to remove residual exosomes. OVA antigen was added 
at a final concentration of 25 μg/mL (OT-I) or 200 μg/mL (OT-II) for 48 or 72 hours, 
respectively. Blocking α-PD-1 antibody (40μg/mL, 60μg/mL) for OT-I and OT-II was 
added to culture along with OVA. Following culture cells were surfaced stained with 
CD4/APC and CD8/APC for 20 min. Cells were then fixed (Fixation Buffer, Biolegend) 
and permeabilized (Intracellular Staining Perm Wash Buffer, Biolgend) prior to 
overnight intracellular staining with IFN-γ.  
2.2.7 Quantitative PCR  
Total RNA was extracted using TRizol (Invitrogen) and isolated according to 
manufacturer’s instructions. cDNA was generated using the iScript cDNA Synthesis 
Kit (Bio-Rad). mRNA expression analysis was carried out using iQ SYBR Green (Bio-
Rad). RNA concentration was quantified using NanoDrop RNA 6000 nano-assays and 
analyzed using the CFX Connect PCR Machine (Bio-Rad). See Table S2 for the 
primer sequences.  
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2.2.8 Cytokine and ELISA measurement 
Supernatant was isolated from culture conditions, centrifuged at 6000rpm for 5 
minutes to remove cellular debris and transferred to a new Eppendorf tube for storage 
at -20°C till use. Cytokine array was performed using the Proteome Profile Mouse 
Cytokine Array Panel A (R&D Systems Inc, Minneapolis, MN) according to the 
manufacturer’s instructions. ELISA MAX IL-6 and IL-10 kits (Biolegend) were used 
according to manufacturer’s instructions.  
2.2.9 Western blot 
F4/80+ cells were sorted using FACS Aria and the stimulated according to 
experimental design. Macrophage proteins were separated using SDSPAGE 10% Tris-
HCl gels and transferred onto PVDF membranes (Millipore, Cat# IPVH00010). The blots 
were blocked with 5% BSA at room temperature for 1 hour and incubated overnight at 
4°C with listed primary antibodies, followed by incubation with HRP-conjugated 
secondary antibodies (GE Healthcare) at room temperature for 1 hour. The membrane 
blots were developed with Amersham ECL Prime Western Blotting Detection Reagent 
(GE Healthcare, Cat # RPN2232) and detected through Medical Film Processor (Konica 
Minolta Medical & Graphic, Inc. Model: SRX-101A).  We used Precision Plus Protein™ 
Kaleidoscope™ Prestained Protein Standards as a standard protein marker (Bio-Rad, 
Cat# 1610375) 
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Primary antibody list 
Antibody Name Vendor Catalog 
Number 
Phospho-NF-κB p65 (Ser536) (93H1) Cell Signaling 
Technology 
3033 
NF-κB p65 (D14E12) Cell Signaling 
Technology 
8242 
PD-L1 R&D Systems AF1019 
Β-Actin Sigma A5316 
HMGB-1 Cell Signaling 
Technology 
6893S 
2.2.10 Immunofluorescence staining  
To detect exosome uptake in F4/80+ peritoneal macrophages, cells were cultured with 
GFP+ LLC exosomes (40μg/mL) for a one or two hour incubation on glass cover slips 
pre-coated with poly-L lysine. Slides were incubated overnight with rat anti-mouse 
F4/80 (1:100). Lung samples from in vivo experiments were frozen in OCT and stored at 
-80°C.  Sections of lung approximately 8 µm were fixed with cold acetone for 15 minutes 
followed by 30 minutes of air drying. Slides were then blocked using 20% FBS in PBS 
for 1 h. Primary Ab staining occurred overnight at 4°C in humidified staining container 
with antibodies to PD-L1 (1:100), CD11b (1:100), and F4/80 (1:100).  
2.2.11 In vivo Syngeneic Tumor Metastasis Model  
LLC (0.5x106, in 100μl PBS) or Rab27-/-/SCRAM 4T-1 (1.2x106, in 100μl PBS) cells 
were injected subcutaneously into the flanks of C57BL/6 mice or orthotopically in the 
mammary glands of BALB/c mice, respectively. The mice were euthanized when the 
tumor diameter reached 10mm. Lung tissue was isolated and weighed prior to 
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enzymatic digestion (collagenase (5g/L), Hyaluronidase(0.4g/L), DNAse I (0.15g/L)) 
for 35 minutes with rotation at 37°C. Following digestion, RBC’s were lysed using 
ACK and resuspended in RPMI-1640 as a single cell suspension. Lung tissue was 
also fixed in OCT for hematoxylin and eosin staining or for confocal microscopic 
analysis.   
2.2.12 Exosome-mediated Metastasis Model 
The experiment was designed as previously described 76. Briefly, 8-10 week old 
C57BL/6 mice were subcutaneously injected in the flank with GFP+ LLC (0.85x106, 
100μl PBS) cells. Seven days post-injection, LLC exosomes or control MLE-12 
exosomes (10μg in 100μl PBS) were injected intravenously every three days for three 
weeks. Lung tissue samples were frozen in OCT at -80°C. Lung tissue was 
enzymatically digested (collagenase (5g/L), Hyaluronidase(0.4g/L), DNAse I 
(0.15g/L)) for 35 minutes with rotation at 37°C. Whole lung cells (5x106) were frozen 
in TRIzol for RNA extraction. Similarly, 8-10 week old C57BL/6 mice were injected i.v. 
with LLC exosomes (10μg, in 100μl PBS) every 2 days for 2 weeks prior to lung 
acquisition and analysis via RT-PCR for metastasis-associated markers.  
2.2.13 In vivo tracking of fluorescently labeled exosomes 
Purified exosomes were labeled according to the previous protocol 70. Briefly, 
exosomes were incubated for 10 minutes with Vybrant DiI (ThermoFisher, 1:1000 
dilution). Excess dye was removed by washing in 20mL of PBS at 100,000 x g (90 
minutes) to generate final DiI labeled exosomes. Exosomes were then intravenously 
injected into C57BL/6 mice (40 μg in 100μl PBS) and lung, bone marrow, and spleen 
were isolated 24 hours later and assessed for uptake via Flow cytometry.  
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2.2.14 Human Samples   
Samples were obtained as approved by the University of Louisville Institutional 
Review Board. Draining LN were obtained from lung transplant donors during lung 
resection and from cancer patients during tumor resection and/or biopsy. Patient 
information was summarized in Table S1. PBMCs were obtained from healthy donors. 
Informed consent was obtained from all donors prior to sample collection. For flow 
cytometry analysis, cells were stained with Fixable Viability Dye/APC-Cy7, CD14/PE, 
CD45/Alexa Fluor 700, CD16/FITC, CD11b/ Biotin, PD-L1/Pe-Cy7, CD66b/PE Dazzle, 
CD68/Percp, HLA-DR/APC, CD33/BV605, CD63/BV650, CD206/BV421, TIM-3/Biotin, 
CD8/PE, CD45RO/FITC, CD3/PerCP, CD103/PE/Dazzle 594, γδ TCR/APC, PD-1/PE-
Cy7, CD4/BV60, CD69/BV650, CD45RA/BV421. Table S3 provided a full antibody list. 
Cells from patient dLN samples were sorted for YKT6 RT-PCR analysis using CD45-
PE on a FACS Aria. Data was analyzed using Cytobank software to generate viSNE 
plots. 
2.2.15 In vitro Human suppression assay 
The human T cell suppression assay was performed according to the previously 
published protocol 77. Briefly, donor PBMCs were sorted on a BD FACsAria for CD14+ or 
CD3+ expression. The CD14+ cells were plated in a 96-well U-bottom plate (0.5x105 
cells/well) and stimulated with 40 μg/mL of HBEC or A549 exosomes for 48 hours. The 
96 U-bottom plate had previously been coated with anti-human CD3 Abs (clone:OKT3) 
(1 µg/mL) in 100μL PBS at 37°C for 4 hours. The CD3+ T cells were then labeled with 1 
μM of the fluorescent dye 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE, 
Invitrogen), according to the manufacturer’s instructions. Wells were gently washed 
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twice with PBS before the addition of cells. CFSE-labeled responders (1.0x105 cells 
/well) were mixed with previously stimulated CD14+ cells in a 1:2 ratio and co-cultured 
for 4 days in the complete cell culture media. The CFSE signal was analyzed by flow 
cytometry on gated on both CD4+ and CD8+ lymphocytes.  
To measure the IFN- production, 1.0x105 autologous sorted CD3+ T cells stimulated 
with plate-bound anti-human CD3 Ab were co-incubated with previously stimulated 
CD14+ subsets in a 1:2 ratio for 48 hours in 96 well U-bottom plate. BD GolgiStop and 
BD GolgiPlug were added into the cell cultures during the last 12 hours. Surface stained 
cells were fixed with Fixation Buffer (Biolegend) for 20 minutes. The fixed cells were 
permeabilized with Intracellular Staining Perm Wash Buffer (Biolegend) and then stained 
with the anti-human IFN- (Biolegend, clone: 4S.B3). The percent of intracellular IFN- 
positive CD4+ and CD8+ T cells was analyzed by flow cytometry. 
2.2.16 In vitro human culture 
A549 exosomes or HBEC exosomes were added (40μg/mL) to previously sorted 
CD14+ myeloid cells (0.5x105, 48 well plate) and stimulated for 16 hours. TLR2 
blocking antibody (TLR2 Monoclonal Antibody (TL2.1), eBioscience) was added at 
40μg/mL to sorted CD14+ cells for 30 min at RT before stimulation with 40μg/mL of 
A549 exosomes. Sorted CD14+ cells were stimulated with recombinant human HMGB-1 
(4μg/mL and 10μg/mL, Cat# 1690-HMB, R&D Systems, Minneapolis, MN) for 16 hours. 
2.2.17 Statistical analysis 
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All results were repeated in at least three independent experiments, and data from 
one representative experiment was shown. All statistical analyses were performed 
using GraphPad PRISM software unless otherwise noted (version 8.0, Irvine, CA, 
USA). All experiments that compared two conditions used unpaired Student’s t tests. 
Those that compared three or more conditions used a one-way ANOVA with multiple 
comparisons. A value of p< 0.05 (two-sided) was considered statistically significant. 
Data are represented as mean ± SEM.  
 
2.2.18 PCA analysis 
To collectively assess the relationships of myeloid and T cell markers of human samples 
screened in this study in the context of disease status, we conducted Principal 
Component Analysis (PCA) using estimated cell marker percentages in each of the 9 
NSCLC and 10 HD samples. Within the R statistical environment (https://www.r-
project.org/), PCA was performed using the prcomp() function, with the “scale” 
parameter set to “TRUE”. The PCA plot was generated using the R package 
“factoextra”, including 95% confidence ellipses. To assess the statistical association of 
the first principal component and disease status, linear regression was conducted using 
the R lm() function, in which disease status of each NSCLC and HD subject was treated 
as the dependent variable and the first principle component scores were treated as the 
independent variable.  
 
2.2.19 TCGA Nodal Status Analysis 
RNA-seq data was downloaded from TCGA for several cancer types. The cases with 
nodal status were kept. Deseq 2 was run on the raw counts between cases with nodal 
status N0 and all other nodal status (N1,N2,N3). Plots were made with Deseq2's function 
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plotCounts with counts normalized by the library size. The p value reported was adjusted 
to correct for false positives due to multiple testing.  
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2.3 RESULTS 
2.3.1 Exosomal characterization and trafficking 
Exosomes were isolated from the supernatants of the murine lung 
adenocarcinoma cell line, Lewis Lung Carcinoma (LLC) 73. Size confirmation of exosome 
isolates demonstrated particles averaging 185nm, which is slightly larger than the 
previously reported size range of 20-150 nm73 (Figure 1A). Protein array analysis 
confirmed surface expression of known exosome markers including CD63, CD81, 
Annexin 5 (ANXA5), and TSG101 (Figure 1B). 
To confirm uptake of exosomes by CD11b+ macrophages in the lung, we injected 
DiI-labeled exosomes intravenously into WT mice. We then harvested lung, spleen, and 
bone marrow to look at exosome uptake and distribution. Looking specifically at the 
CD11b+ F4/80+ compartment, we found that lung CD11b+ cells had the highest uptake 
compared to those harvested from spleen and bone marrow (Figure 1C).  
2.3.2 The effect of TDE on macrophages in a pre-metastatic niche 
We intravenously injected non-GFP LLC or control mouse lung epithelial cell 
(MLE-12) exosomes into wild type (WT) mice that 7 days prior had been subcutaneously 
injected with LLC-GFP tumor cells (Figure 2A). While mice treated with the MLE-12 
exosomes showed no difference compared to untreated tumor-bearing mice, LLC 
exosome treated mice had an increased number of micro-metastases as assessed by 
the percentage of LLC-GFP+ cells in the lung (Figure 2B). Fluorescent microscopy 
analysis confirmed these results (Figure 2C). Further confocal analysis of the lung  
tissues demonstrated increased PD-L1 co-expression with both CD11b and F4/80 in 
LLC exosome-treated mice suggesting that the exogenously administered TDE were 
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Figure 1. Exosome Isolation and Uptake.  (A) Size characterization of exosome 
centrifugation isolate using Nanosight NS300. Representative plot for n=3 independent 
experiments (B) Exo-check antibody array to confirm proper isolation of LLC exosomes 
via ultracentrifugation of culture supernatants. GM-130: cis-golgi-matrix protein (monitor 
cellular contamination), TSG101: Tumor susceptibility gene, ANXA5: Annexin A5, 
EpCAM: epithelial cell adhesion molecule, CD63:LAMP-3, CD81, ALIX: programmed 
death 6-interacting protein, ICAM1- intracellular adhesion molecule 1, FLOT1: flotillin 1, 
positive: control for HRP detection. Representative WB for n=3 independent experiments 
with similar results.  (C) In vivo injection of DiI labeled LLC exosome (40 μg/mouse) to 
determine biodistribution among bone marrow (top), spleen (middle), and lung (bottom). 
n=3. The data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, (unpaired 
student’s t test). 
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To determine the effect exosomes alone have on priming a metastatic site, we 
intravenously injected WT mice with LLC exosomes for two weeks. LLC exosome 
treatment significantly increased expression levels of known metastasis markers, MMP9, 
S100a8, and S100a9 (Figure 3A), which have been associated with increased tumor cell 
invasion, migration, and colonization at the metastatic site 54. 
2.3.3 TDE polarize macrophages towards an immunosuppressive phenotype 
Similar to the in vivo myeloid phenotype, F4/80+ peritoneal macrophages treated in 
vitro with TDE showed an increase in surface PD-L1 expression as compared with 
control MLE-12 exosomes or macrophages alone (Figure 3B). LLC exosome treatment 
also increased expression of activation marker, CD80, as compared to controls (Figure 
3C). Stimulation with exosomes isolated directly from subcutaneous LLC tumors also 
demonstrated increased PD-L1 expression thus eliminating the possibility that the 
phenotype was an in vitro artifact from cell line culture (Figure 3D)78. Additionally, to 
emphasize this phenotype is not only limited to lung adenocarcinoma, peritoneal 
macrophages were treated with exosomes isolated from 4-T1 breast cancer, MC38 
colon cancer, and B16F10 melanoma cell lines all of which demonstrated increased PD-
L1 expression (Figure 3E). Confocal analysis of F4/80+ peritoneal macrophages 
confirmed increased uptake of FITC+ LLC exosomes over time (Figure 4A).  
However, the question remained as to whether exosomal uptake was increasing 
endogenous production of PD-L1 by the macrophages or whether the macrophages 
were acquiring the PD-L1 from the exosomes. Western blot analysis confirmed that LLC 
exosomes do express PD-L1, similar to previously reports (Figure 4B)62, 66, 72. However, 
RT-PCR analysis of macrophages treated with LLC exosomes demonstrated a  
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LLC Exo.













































Figure 2. The effect of TDE on macrophages in a pre-metastatic niche. (A) Schematic 
for experimental design (B-D). (B) Micro-metastatic burden was quantified by LLC-GFP% in 
the lungs of subcutaneous GFP-LLC tumor-bearing mice treated i.v. with 10 μg/mL MLE-12 
or LLC exosomes every three days for 3 weeks (ctrl n=6, MLE-12 Exo. n=5, LLC Exo. n=6). 
(C) Confocal microscopic analysis of lung GFP+ micro-metastases from primary 
subcutaneous LLC tumor-bearing mice. (D) Confocal microscopic analysis of PD-L1 
expression in LLC Exo- or LLC Exo+ treated lungs (left) and PD-L1 co-expression with 
CD11b and F4/80 in LLC Exo+ mice (right). Scale bar, 100μM. The data are shown as mean 


























































































































































































































Figure 3. TDE stimulation drives PD-L1 expression in macrophages. (A) Metastasis-
associated marker gene expression in the lungs of WT mice treated i.v. with LLC exosomes 
every 2 days for two weeks compared WT control. The data are normalized to WT gene 
expression level. n=4 control, n=8 LLC Exo. (B) Expression of PD-L1 by flow cytometry in 
peritoneal macrophages stimulated with MLE-12 exo. or LLC Exo. (40μg/mL) for 16 hours. 
Representative histograms and summarized MFI are shown. MFI= mean fluorescent intensity. 
n=3 per group. ***p<0.001, ****p<0.001, one-way ANOVA with multiple comparisons. (C) 
Expression of CD80 in peritoneal macrophages stimulated with 40μg/mL MLE-12 exo. or LLC 
Exo. for 16 hours. MFI= mean fluorescent intensity. n=3 per group., **p<0.01 one-way 
ANOVA with multiple comparisons.  (D) Expression of PD-L1 in peritoneal macrophages 
treated with exosomes isolated from subcutaneous LLC tumors compared to MLE-12 controls. 
Tumors were excised from the flank, digested, and cultured in vitro for ultracentrifugation 
exosome isolation. n=4 mice per group. ****p<0.001, one-way ANOVA with multiple 
comparisons. (E) PD-L1 expression in peritoneal macrophages treated with exosomes 
(40μg/mL) from Breast cancer (4-T1), Colon cancer (MC38), and Melanoma (B16-F10) cell 
lines. n=3 per group. The data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, 






significant increase in PD-L1 mRNA expression indicating that de novo synthesis of PD-
L1 is likely a greater source of PD-L1 (Figure 4C). Taken together, these data suggest 
that TDE are taken up selectively by F4/80+ macrophages, resulting in increased 
endogenous production of PD-L1 both in vitro and in vivo, and promote primary tumor 
progression and metastasis in the lung.  
We next explored if TDE stimulation impacts the functionality of macrophages. We 
first performed a cytokine array on the supernatants from the 16 hour macrophage 
culture (Figure 5A). As compared to macrophages alone, as well as macrophages 
stimulated by MLE-12 exosomes, the TDE stimulated macrophages displayed prominent 
increases in the secretion of TNFα, TIMP-1, MCP-1, IL-10, IL-6, IL-1ra, G-CSF, and 
CXCL1. Notably, all cell supernatants were negative for IFN-γ thus eliminating this as a 
potential mechanism for PD-L1 upregulation79. ELISA analysis also confirmed increased 
IL-6 and IL-10 production, two cytokines that are hallmarks of cancer-related 
inflammation (Figure 5B) 80. The immunosuppressive phenotype was further 
characterized by increased arginase-1(Arg-1) and vascular endothelial growth factor 
(VEGF) expression (Figure 5C). However, a dramatic increase in iNOS production was 
also noted, supporting the emerging notion that macrophages within the tumor 
microenvironment often display a mixed M1/M2 phenotype56.  
To further examine the impact of TDE-induced macrophages on effector T cell 
function, we pre-treated peritoneal macrophages with control MLE-12 or LLC exosomes 
prior to co-culture with OVA transgenic T cells. As depicted in Figure 6A, CD8+ T cells 
displayed a dramatic decrease in both cell proliferation as well as IFN-γ production when 
co-cultured with TDE-polarized macrophages. This phenotype was largely rescued when 
neutralizing α-PD-1 was added suggesting that the PD-L1 expression on macrophages  
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Figure 5 TDE polarize macrophages towards an immunosuppressive phenotype. (A) 
Representative cytokine array panels of supernatants taken from 16 hour culture of peritoneal 
macrophages stimulated with media alone (top), MLE-12 exosomes (middle), or LLC exosomes 
(bottom). Representative plots and summarized mean pixel density of each protein are shown 
(n=3). (B) IL-6 and IL-10 concentration detected by ELISA from supernatants of 16 hour peritoneal 
macrophages stimulated with or without LLC exosomes (40μg/mL). **p<0.01, ****p<0.001 
(unpaired student’s t test). (C) The mRNA expression levels of Arginase-1 (Arg-1), vascular 
endothelial growth factor (VEGF), and inducible nitric oxide (iNOS) in peritoneal macrophages 
treated alone or with 40 μg/mL MLE-12 or LLC exosomes for 6 hours. n=3. The data are shown as 














































Figure 4. TDE drive de novo production of PD-L1. (A) Confocal microscopic analysis of 
GFP+ LLC exosome uptake expression in F4/80+ peritoneal macrophages treated for 
indicated period of time. Scale bars, 20μm. (B) Representative WB analysis of PD-L1 
expression in macrophages stimulated with IFN-γ, macrophages alone, and LLC exosomes. 
(C) The mRNA expression of PD-L1 in peritoneal macrophages following 6 hour LLC exo. 
stimulation. Data was normalized to control expression level. The data are shown as mean ± 











































































































































































































































































































Figure 6. TDE restrain T cell effector functioning. (A) LLC exosome polarized peritoneal 
macrophages suppress OT-I T-cell proliferation (top) and IFN-γ production (bottom) in a PD-L1 
dependent manner. Peritoneal macrophages were polarized with MLE-12 or LLC exosomes 
(40 μg/mL) for 48 hours prior to co-culture with purified OVA-specific CD8 T cells in the 
presence of OVA (25 μg/mL) for two days with or without α-PD-1 (40 μg/mL). Representative 
histograms and summarized data are shown (n=3). (B) LLC exosome polarized peritoneal 
macrophages suppress OT-II T-cell proliferation (top) and IFN-γ production (bottom) in a PD-L1 
dependent manner. Representative histograms and summarized data are shown (n=3). The 





is, at least in part, causing functional inhibition of effector T cells. A similar phenotype 
was seen with CD4+ T cells (Figure 6B).   
2.3.4 TDE mediate PD-L1 expression through TLR2 and NF-κB 
Toll-like receptors (TLRs) play an important role in innate immunity and are often 
found on sentinel immune cells such as macrophages and dendritic cells. Using mice 
deficient in the TLR adaptor protein MyD88, we found that the increased PD-L1 
expression following LLC exosome stimulation was completely abrogated in MyD88-/- 
macrophages (Figure 7A). To identify which specific TLR pathway was involved, 
peritoneal macrophages from TLR2-, TLR4-, TLR6-, TLR7-, and TLR9-deficient mice 
were stimulated with TDE. As seen in Figure 7B, TLR2-deficient macrophages 
specifically lost the increased PD-L1 expression, while all other TLR-deficient mice 
showed normal PD-L1 expression following TDE stimulation.  
To solidify the finding that TLR2 ligation is necessary for exosomes to mediate their 
effect on macrophages and promote pre-metastatic niche formation, we repeated our 
initial in vivo LLC-GFP subcutaneous tumor model using TLR2-/- mice. There was no 
difference in LLC-GFP% in the lungs of the TDE-treated group compared to the controls 
in TLR2-/- mice (Figure 7C). Furthermore, when compared to WT, the LLC-GFP% was 
overall significantly reduced in the TLR2-/- mice (Figure 7D). Confocal microscopy 
analysis showed no obvious tumor foci in the lungs of TDE treated TLR2-/- mice (Figure 
7E). Collectively, these results indicate that signaling through TLR2 is required for TDE 
to mediate upregulated PD-L1 expression on macrophages and influence the 





























































































































Figure 7. TDE mediate PD-L1 expression through TLR2  (A) The expression of PD-L1 on WT 
or MyD88-/- peritoneal macrophages that were stimulated with or without LLC exosomes (40 
μg/mL) for 16 hours assessed by flow cytometry. (B) Expression of PD-L1 assessed by flow 
cytometry in WT or TLR2-/- peritoneal macrophages following stimulation with LLC exosomes (40 
μg/mL) for 16 hours (left). Macrophages from TLR4-/-, TLR6-/-, TLR7-/-, and TLR9-/- showed normal 
PD-L1 expression compared to WT control following TDE stimulation indicating those pathways 
are not involved in LLC exosome signaling (right). n=3 mice per group. (C) Summary of GFP+ 
micrometastases in the lungs of TLR2-/- mice that had previously been injected subcutaneously 
with GFP-LLC tumor cells (1.0x106) and then treated i.v. with 10 μg/mL MLE-12 or LLC 
exosomes every three days for 3 weeks Control n=5, MLE-12 Exo n= 4, LLC Exo n= 5 mice per 
group. (D) Comparison of GFP+ micrometastases between WT and TLR2-/- LLC Exo treated 
mice. n= 5 mice per group. (E) Confocal analysis of GFP+ micrometastases in the lungs of TLR2-/- 
mice. The data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, (one-way ANOVA 
with multiple comparisons). 
C. D. E. 
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Previous studies have linked increased PD-L1 expression to activation of the NF-κB 
pathway 81 and TLR2 is well-known to activate the NF-kB pathway. To probe whether 
exosomal stimulation activates the NF-κB cascade downstream of TLR2, we 
performedWestern blot analysis in macrophages stimulated with control or TDE. 
Stimulation with LLC exosomes, but not control MLE-12 exosomes, increased 
phosphorylation of NF-kBp65 (Figure 8A). In addition, inhibition of NF-κB with BAY-11-
7082 (BAY) reduced PD-L1 expression in macrophages as assessed by flow cytometric 
assay (Figure 8B). These results were further confirmed by RT-PCR analysis (Figure 
8C). Another prominent signaling pathway previously reported to affect PD-L1 
expression is the mechanistic/mammalian target of rapamycin (mTOR) pathway 82. LLC 
exosome stimulation of macrophages deficient in the adaptor protein Raptor or Rictor for 
the mTOR complex 1 (mTORC1) or mTORC2 resulted in unaltered levels of PD-L1 
expression (Figure 8D), suggesting that this pathway is not involved in PD-L1 
upregulation on macrophages induced by TDE.   
2.3.5 Exosomal HMGB-1 activates TLR-2 
  Having demonstrated TLR2 as the receptor through which TDE signal, we next 
determined which specific exosomal factor activates TLR2. One known ligand for TLR2 
that has been shown to positively correlate with NSCLC lymph node metastasis is high-
mobility group box-1 (HMGB-1) 83. Overexpression of HMGB-1 has been demonstrated 
in many types of cancer 83, 84, 85. Indeed, LLC whole cell lysate and TDE indicated 
significant expression of HMGB-1 (Figure 9A). Stimulation of peritoneal macrophages 
with recombinant murine (rm)HMGB-1 resulted in increased PD-L1 expression (Figure 
9B). Conversely, stimulation of MyD88-/- (Figure 9C) or TLR2-/- (Figure 9D) peritoneal 
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Figure 8. TDE drives PD-L1 expression through NF-ĸB  (A) Activation of NF-κB signaling cascade 
in peritoneal macrophages following stimulation with MLE-12 or LLC exosomes (40 μg/mL) at 
indicated time determined by WB analysis. (B) Peritoneal macrophages were pre-treated with the NF-
κB inhibitor, BAY-11-7082 (0.2μg/mL) for 1 hour prior to 16 hour stimulation with LLC exosomes (40 
μg/mL). PD-L1 expression was assessed by flow cytometry. Data was normalized to the control. n=3. 
(C) The mRNA expression level of PD-L1 in peritoneal macrophages pre-treated with the NF-κB 
inhibitor, BAY-11-7082 (0.2μg/mL) for 1 hour prior to 6 hour LLC exo. stimulation. n=3. (D) PD-L1 
expression in LysM-cre;Rictorfl/fl (left) and LysM-cre;Raptorfl/fl (right) peritoneal macrophages 
compared to Rictorfl/fl, Raptorfl/fl controls following 16 hour stimulation with LLC exosomes. (n=3 per 
group). The data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (one-way 
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Figure 9. HMGB-1 on TDE induces TLR2 mediated PD-L1 expression (A) Representative 
WB analysis of HMGB-1 expression in LLC whole cell lysate and LLC exosomes. (B) PD-L1 
expression in peritoneal macrophages stimulated with murine HMGB-1 (rmHMGB-1) for 16 
hours. Representative histograms and summarized MFI data are shown. n=5. (C) 
Comparison of PD-L1 expression between WT and MyD88-/- peritoneal macrophages 
following stimulation with rmHMGB-1. Representative histograms and summarized MFI are 
shown. n=4 per group. ***p<0.001 (one-way ANOVA with multiple comparisons). (D) PD-L1 
expression in TLR2-/- peritoneal macrophages compared to control following LLC exo. 
stimulation for 16 hours. Summarized MFI data is shown. n=3. **p<0.01, ***p<0.001 (one-
way ANOVA with multiple comparisons). (E) Expression of HMGB-1 in either shControl or 
shHMGB-1 primary 4T1 subcutaneous tumors (left), H&E staining of lung (middle) and 
summarized number of metastatic tumor nodules (right) in the lungs of shControl or 
shHMGB-1 tumor-bearing mice. The data are shown as mean ± SEM. **p<0.01 (unpaired 





knockdown of HMGB-1 in 4T-1 breast cancer cells decreased overall expression of 
HMGB-1 in primary tumor and accordingly decreased the number of metastatic nodules 
in the lung (Figure 9E). Taken together, these data suggest that tumor-derived exosomal 
HMGB-1 is at least one factor responsible for mediating TLR2 dependent PD-L1 
upregulation and subsequent tumor metastasis.  
2.3.6 TDE drive PD-L1 expression in vivo 
We next examined how the TDE driven phenotype impacts the immune landscaping 
of a pre-metastatic niche in vivo. We particularly focused on the lungs of WT mice that 
had previously been injected subcutaneously with LLC cells. H&E staining confirmed the 
lungs were negative for overt primary tumor metastasis at end point (Figure 10A). 
Analysis of the interstitial (IM:CD11b+/F4/80+) and the alveolar (AM:CD11blow/-/F4/80+) 
macrophage populations (Figure 10B) showed that the IM population dramatically 
increased in the tumor-bearing mice while the AM population remained largely 
unchanged compared to the control. Furthermore, the IMs demonstrated increased PD-
L1 expression within this pre-metastatic tumor environment whereas the AMs showed no 
change. Other noticeable effects within the lung included a decrease in monocytes 
(CD11b+Ly6C+) and an increase in MDSCs (CD11b+Gr-1+) in tumor-bearing mice (Figure 
10C). 
Next, we aimed to demonstrate that TDE, specifically, are responsible for mediating 
the increased PD-L1 expression in the IM compartment allowing for priming of lung 
cancer metastasis. In order to address this question, we used CRISPR/CAS-9 
technology to edit RAB27a gene expression in 4T-1 breast carcinoma. Rab27a is a 
critical regulatory protein necessary for exosome secretion from the plasma membrane 
86. Given that breast cancer, particularly triple-negative breast cancer, often
metastasizes to the lungs, a triple negative primary 4T-1 orthotopic breast cancer with 
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metastasis to the lung served as a clinically relevant model. Western blot analysis 
showed about a 50% reduction in Rab27a expression following transfection (Figure 
11A). There was no difference in overall primary tumor burden between the scrambled 
(SCRAM) control and the Rab27-/- cells (Figure 11B). However, the lung resident CCR2- 
IM population that expanded the most in the exosome competent tumor was significantly 
diminished in RAB27-/- tumors (Figure 11C). Moreover, depletion of RAB27 specifically 
decreased PD-L1 expression in the CCR2- IM compartment and left the CCR2+ 
unchanged (Figure 11D). These data suggest that TDE specifically impact the tissue 
resident interstitial macrophages rather than the recruited bone marrow-derived 
macrophages to drive PD-L1 expression in the pre-metastatic niche. The AM 
compartment displayed no change following RAB27 depletion (Figure 11E).  
The collective immune landscape in the lung following RAB27 depletion 
demonstrated an overall more active immune profile. Specifically, there was a decrease 
in the percentage of immunosuppressive MDSCs (Figure 12A) and analysis of the T-cell 
compartment within the lung demonstrated an increase in percentage of CD8+ T cells 
(Figure 12B) with a trending decrease in exhaustion marker PD-1 expression (Figure 
12C).  Conversely, the overall percentage of CD4+ T cells in the Rab27-/- tumor-bearing 
mice was unchanged but there was a significant decrease in PD-1 expression (Figure 
12D). These results together indicate that circulating exosomes from primary tumors are 
capable of infiltrating in the lung and increasing the expression of PD-L1 on the tissue 
resident interstitial macrophage population, inducing an exhausted T cell phenotype and 























































































































Figure 10. TDE augment tumor growth and metastasis (A) H&E section of naive 
(top) and LLC subcutaneous tumor bearing (bottom) lungs. Scale bar, 50μm. (B) 
Percentage of F4/80+CD11b+ IM and representative PD-L1 expression plots in control 
versus LLC tumor bearing mice (top panels). F4/80+CD11c+ AM percentage and 
overall PD-L1 expression in the lungs of control and LLC tumor bearing mice (bottom 
panels). control n=4; LLC tumor n=9. (C) Recruitment of circulating monocytes 
(CD11b+Ly6C+) and myeloid-derived suppressor cells (CD11b+Gr-1+) in the lungs of 
control versus tumor bearing mice. The data are shown as mean ± SEM. **p<0.01, 



















































































































































Figure. 11 In vivo assessment of TDE influence on myeloid PD-L1 (A) 
Representative WB for Rab27a protein expression in CRISPR/CAS9 generated 
Rab27a-/- 4T-1 tumor cells (B) Primary tumor volume 28 days post injection with 
1.2x106 SCRAM or Rab27a-/- 4T-1 tumor cells (n=11 per group). (C-D) CCR2 and 
PD-L1 expression on CD11b+ IM in the lungs of SCRAM versus RAB27-/- tumor 
bearing mice. n=12 per group. (E) Percentage and PD-L1 expression on 
F4/80+CD11c+ AM in the lungs of SCRAM versus RAB27-/- tumor bearing mice. The 














































































































































Figure. 12 In vivo assessment of TDE influence on immune compartment (A) 
Recruitment of MDSCs (CD11b+Gr-1+) into the lungs of SCRAM or Rab27-/- tumor bearing 
mice. Scram n=9; Rab27-/- n=7. (B-C) Percentage of CD8+ T cells and PD-1 expression in the 
lung of SCRAM versus RAB27-/- tumor bearing mice (D) Percentage and PD-1 expression of 
CD4+ T cells in the lung of SCRAM versus RAB27-/- tumor bearing mice. Representative dot 
plots and summarized data are shown. The data are shown as mean ± SEM. *p<0.05 





2.3.7 TDE polarize human CD14+ cells to an immunosuppressive phenotype 
To ascertain the clinical relevance of our findings, we examined if we could 
recapitulate the phenotype using exosomes derived from human tumor cells. As shown 
in Figure 13A, exosomes isolated from the human NSCLC A549 cell line but not the 
control human bronchial epithelial cell line (HBEC) significantly increased PD-L1 
expression on CD14+ monocytes. Co-culture of these treated CD14+ cells with 
autologous CD3+ T cells in the presence of plate bound anti-CD3 mAbs demonstrated 
that A549 TDE polarized CD14+ cells drastically inhibited both CD4 and CD8 T cell 
proliferation as well as IFN-γ production from CD8+ T cells (Figure 13B). Stimulation with 
recombinant human HMGB-1 increased PD-L1 expression in CD14+ cells suggesting a  
least a partial role for HMGB-1 induced TLR2 activation (Figure 13C). Addition of TLR2-
blocking antibody dramatically decreased PD-L1 expression indicating human exosomes 
also signal through TLR2 to drive PD-L1 expression (Figure 13D).  
To further examine how our pre-clinical model could correlate with clinical outcomes, 
we obtained draining lymph node (dLN) samples from NSCLC patients that were 
negative for tumor cell infiltration to best mimic a pre-metastatic niche (Table 1). We 
compared those LNs to the LNs from lung transplant donors, which were considered to 
be healthy donors in this case. Overall analysis of surface marker expression within the 
myeloid cell compartment indicated increased levels of CD16+, CD33+, CD63+, CD68+, 
and CD206+, suggesting an overall activated, classic M2 phenotype in cells from patient 
samples compared to those of healthy donors (Figure 14A). Furthermore, when 
specifically looking at CD206 and PD-L1 co-expression in the CD68+ macrophages, 
there was roughly double the expression in the NSCLC cohort compared to healthy 
controls (Figure 14B). Notably, macrophage CD206/PD-L1 co-expression positively 
correlated with PD-1 expression on the CD8+ T cells within the dLN (Figure 14C). viSNE 
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analysis of the CD4+ T cell population also demonstrated increased PD-1 expression 
compared to healthy controls and a positive trending correlation with the macrophage 
CD206/PD-L1 expression (Figure 14D). Taking the immune phenotype markers 
together, principal component analysis (PCA) of the myeloid and T cell populations 
within the LNs demonstrated a significant difference in mean expression pattern 
between NSCLC patients and healthy donors (Figure 14E). Linear regression analysis of 
PC1 demonstrated the significance of disease state in accounting for variance within this 
profiling.  
To determine whether the immunological changes within the dLN were associated 
with exosomal phenotype, we turned to the TCGA dataset to see if we could find any 
correlation between exosome release genes and nodal metastasis. We divided patients 
into two groups based on nodal staging, NX/N0 were considered negative whereas N1-
N3 were considered positive for metastasis. Our screening revealed that two exosome 
released genes, YKT6 (Figure 15A) and TSG101 (Figure 15B), had higher expression in 
the primary tumor of lung adenocarcinoma patients with positive nodal metastasis 
compared to nodal negative. A similar phenotype for YKT6 was also seen in patients 
with colon adenocarcinoma (Figure 15C).  Furthermore, the top quartile of lung 
adenocarcinoma patients expressing YKT6 demonstrated significantly poorer survival 
outcomes when compared to the bottom quartile of YKT6 expressing patients (Figure 
15D).   
We then turned to our own NSCLC patient cohort to substantiate the TCGA dataset 
results. We found that CD45- tumor cells displayed increased expression of YKT6 
(Figure 15E) and TSG101 (Figure 15F) as compared to CD45+ cells sorted from primary 
tumor. Furthermore, there was a trending positive correlation between YKT6 expression 
in the primary tumor cells and PD-L1 expression in the dLN (Figure 15G). TSG101 also 
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showed a trending positive correlation though not as robustly as YKT6 (Figure 15H). 
Grouping the NSCLC patients into cohorts based on their PD-L1 expression level (high 
>10% CD68+CD206+PD-L+ and low <10% CD68+CD206+PD-L+ expression), 
demonstrated a significantly increased YKT6 mRNA level in the PD-L1high cohort over 
the PD-L1low (Figure 15I). These results suggest at least a positive association in our 
NSCLC patient cohort between release of primary tumor derived exosomes and the 
















































































































Figure 13. The effect of human TDE on human macrophages. (A) CD14+ myeloid cells 
were sorted from peripheral blood of healthy donors and stimulated with 40μg/mL of control 
human bronchial epithelial cell (HBEC) or A549 lung adenocarcinoma (A549) exosomes for 
16 hours. PD-L1 expression was determined by flow cytometry (n=3 separate PBMC donors). 
Representative histogram and summarized data are shown. (B) Proliferation of autologous 
CD4+ and CD8+ T cells stimulated with plate bound anti-CD3 Abs in the presence of CD14+ 
cells previously cultured with A549 or HBEC exosomes (40μg/mL) for 48 hours. Data are 
representative from n=3 independent experiments. Representative dot plots and summarized 
data are shown (C) Sorted CD14+ cells were stimulated with the indicated dose of human 
recombinant HMGB-1 protein for 16 hours prior to flow cyotmetric analysis of PD-L1 
expression. Representative histograms and summarized data are shown. n=4 healthy donors. 
(D) Sorted CD14+ cells were stimulated with 40μg/mL A549 exosomes with or without the 
addition of αTLR2 (40μg/mL) or IgG1 blocking antibody. Representative histogram and 
summarized data are shown. The data are shown as mean ± SEM. *p<0.05, **p<0.01, 



































































































































































































Figure 14. Immune phenotyping in dLN of NSCLC patients. (A) The expression of myeloid associated 
markers in lymph nodes of non-cancerous lung transplants (10 healthy donors) versus T1-3N0 NSCLC 
patients (n=9). (B) The expression of CD206 and PD-L1 on CD68+ macrophages in the draining lymph 
nodes of non-cancerous lung transplants (10 healthy donors) versus T1-3N0 NSCLC patients (n=9). (C) 
Pearson correlation between CD206/PD-L1+ macrophages and CD8+ PD-1+ T cells within the dLN. (D) 
Expression levels of CD4 and PD-1 across CD45+ cells from dLN of healthy donors and NSCLC patients 
illustrated in t-SNE plots. (E) Pearson correlation between PD-1 expression on CD4+ T cells and 
CD206/PD-L1 expression on CD68+ myeloid cells in dLN of NSCLC patients. (F) PCA plot of the first two 
principal components (“Dim1” and “Dim2”), depicting the relationships of NSCLC (red triangles) and HD 
(blue circles) subjects. The percent variance explained by each principal component is indicated in 
parentheses. The 95% confidence ellipses and centroids (enlarged symbols) for each group of samples 
(NSCLC and HD) are also shown (left). Boxplot depicting the values for the first principal component, 
partitioned by disease state (NSCLC vs. HD), as determined by PCA (right). ****p<0.0001 generated by 







































































































































Figure 15. Correlation between TDE release and pre-metastatic niche.  (A) Boxplot showing 
YKT6 expression in patients with negative nodal staging (N0) compared to positive nodal staging (N1-
N3) in lung adenocarcinoma (LUAD) patients from the TCGA database. Plots were made with 
Deseq2’s function plotCounts with count normalized to library size. Positive (N1-N3) n=85, Negative 
(NX/N0) n=156 (B) Boxplot depicting TSG101 expression in patients with negative nodal staging (N0) 
compared to positive nodal staging (N1-N3) in lung adenocarcinoma (LUAD). Plots were made with 
Deseq2’s function plotCounts with count normalized to library size. Positive (N1-N3) n=85, Negative 
(NX/N0) n=156 (C) Boxplot depicting YKT6 expression in patients with negative nodal staging (N0) 
compared to positive nodal staging (N1-N3) in colon adenocarcinoma (COAD). Positive (N1-N3) 
n=193, Negative (NX/N0) n=283. (D) Kaplan-Meier survival curve generated by Oncolnc for TCGA 
dataset LUAD patients based on expression profile (High= top 25%) and (low=bottom 25%) of YKT6. 
n=123 per group. **p<0.01 (log rank test). (E) YKT6 expression in CD45+ versus CD45- cells in 
primary tumor from NSCLC patients. n=8. (F) TSG101 expression in CD45+ versus CD45- cells in 
primary tumor from NSCLC patients. n=8. (G) Pearson correlation between YKT6 expression in 
NSCLC tumor CD45- cells and CD206/PD-L1 expression on CD68+ myeloid cells in dLN n=8. (H) 
Pearson correlation between TSG101 expression in NSCLC tumor CD45- cells and CD206/PD-L1 
expression on CD68+ myeloid cells in dLN. n=8. (I) YKT6 mRNA expression levels in NSCLC patient 
primary tumors grouped by CD206/PD-L1 expression level (high >10% CD68+CD206+PD-L+ and low 
<10% CD68+CD206+PD-L+ expression) in CD68+ macrophages within the dLN. n=4 patients per 
group. The data are shown as mean ± SEM. *p<0.05, **p<0.01 (unpaired student’s t test). 
 






















The formation of a pre-metastatic niche is a cornerstone for cancer metastasis. 
Without a favorable local microenvironment, circulating cancer cells will not be able to 
engraft and grow. Immune suppression is one of the defining characteristics of a pre-
metastatic niche and it is believed that one of the key modulators of this phenotype are 
macrophages 35. However, how macrophages acquire their immunosuppressive 
characteristics within the pre-metastatic niche has yet to be clearly elucidated. In this 
study, we demonstrate that TDE polarize tissue resident macrophages towards an 
immunosuppressive phenotype through NF-kB-dependent signaling. 
Immune checkpoint blockade (ICB) therapy using either PD-1 or PD-L1 antibodies 
has demonstrated significant clinical benefit with the overall response rate for NSCLC 
hovering between 17-21% 87. While it was originally thought tumor cells were the main 
source of PD-L1-mediated suppression, recent studies have indicated that PD-L1 
expression on antigen presenting cells (APCs) such as dendritic cells or macrophages 
play a more dominant role in determining efficacy of PD-1 ICB therapy 46, 88. Given the 
importance of PD-L1 on myeloid cells, it is paramount to determine what drives 
expression of PD-L1. PD-L1 expression on exosomes themselves has been credited to 
induce an overall immunosuppressed phenotype in both mice and humans 62. In our 
study, elimination of exosome secretion from the primary tumor decreased expression of 
PD-L1 on lung resident F4/80+CD11b+CCR2- IM and decreased recruitment of MDSCs, 
while increasing effector T cell infiltration. In vitro analysis demonstrated that exosomes 
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from tumor cells alone increased the de novo synthesis of PD-L1 in macrophages. We 
conclude that PD-L1 expression on macrophages induced by TDE is not dependent on 
exosomal PD-L1 transfer. Several lines of evidence support this conclusion including 
increased PD-L1 mRNA levels and a complete dependence on TLR2 and MyD88 
signaling. In an attempt to determine what exosomal factor(s) elicits the TLR2 activation, 
we assayed for the effect of known metastasis-associated protein and TLR2 ligand, 
HMGB-1 on driving PD-L1 expression. UVB radiation of melanoma cells previously has 
been shown to increase their expression of PD-L1 in an HMGB-1 dependent manner 84. 
While they found tumor secreted HMGB-1 signals through RAGE, here we demonstrate 
that exosomal HMGB-1 signals through TLR2 to increase expression of PD-L1 on 
myeloid cells in both mice and humans. Elimination of HMGB1 in primary subcutaneous 
tumors decreased the number of metastatic lesions in the lung pointing towards a 
causative role in tumor metastasis.   
One caveat to mention regarding our studies focuses on the heterogeneity of the 
exosomal pool. Recent studies have shown that there are different subtypes and 
subpopulations of exosomes released from the same parent cell89, 90. Our experiments 
used a single pool of exosomes isolated from cancer or normal tissue cell lines. 
Therefore, going forward, it would be interesting to investigate whether there are 
subpopulations of exosomes within our isolate and how those impact on our phenotype. 
Specifically, are there necessary or identifiable characteristics of a particular exosomal 
subtype that drive PD-L1 expression in myeloid cells?  
In an effort to determine if exosomes contribute to pre-metastatic niche formation in 
human cancer patients, we used dLN samples from cadaveric lung transplant organs as 
healthy controls and compared them to dLN from NSCLC patients. Specifically, we 
chose LN samples from patients with T1N0-T3N0 staging to investigate the immune 
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landscape of LNs that at least by current practices in staging are negative for tumor cell 
infiltration and could best mimic a pre-metastatic niche in humans91. Assuming the 
staging is correct, the patient dLN display an already increased proportion of CD206+PD-
L1+ macrophages, particularly for some patients, as compared to healthy donor controls. 
Macrophage PD-L1 expression positively correlated with PD-1 expression on CD8+ T 
cells. Taken together these findings point towards an altered immune profile despite 
negative nodal staging. 
 To demonstrate a link between nodal metastasis and exosomes from primary 
tumors, we found that out of the 20 known exosome release genes, two in particular, 
YKT6 and TSG101 correlated with positive metastatic nodal staging in the LUAD patient 
cohort within the TCGA database 92. We were able to substantiate this data using dLN 
and primary tumor samples from our own NSCLC patient cohort. Specifically, there was 
a trending correlation between YKT6 expression in the primary tumor cells and PD-L1 
expression on macrophages in the dLN. The lack of significance is most likely due to the 
limited size of the patient samples. Nevertheless, grouping the 8 patients into cohorts 
based on their PD-L1 expression level (high >10% CD68+CD206+PD-L+ and low <10% 
CD68+CD206+PD-L+ expression), YKT6 mRNA levels were significantly increased in the 
high cohort over the low. Collectively, these results suggest that primary tumors capable 
of secreting high amounts of TDE have an increased likelihood of metastasis due to the 
ability of TDE to reprogram the immune landscape within the pre-metastatic site towards 
an immunosuppressive PD-L1+ phenotype on macrophages.  
 A recent study profiling immune activation and evasion throughout the 
developmental stages of carcinogenesis in human lung squamous cell carcinoma found 
an increased abundance of M1 macrophages in high grade lesions and early carcinoma 
as compared to low grade lesions clearly demonstrating the M1 phenotype is not solely 
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pro-inflammatory in nature but could be pro-carcinogenic as well 93. Further analysis of 
these high-grade lesions showed enrichment for CD80, PD-L1, IL-10, and IL-6, an 
immunomodulatory profile that bears a striking resemblance to our TDE-stimulated “non-
classical M1” macrophages. Additional studies in early stage lung cancer have also 
shown that M1 macrophages exhibit the highest expression level of PD-L1 and CD80 
compared to TAM and classical M2 77. Collectively, these data emphasize the potential 
clinical relevance of our study. The presence of PD-L1+, “non-classical M1” 
macrophages along with other tumor promoting characteristics could be used as an 
immune biomarker to indicate early primary carcinogenesis or, as we propose, pre-
metastatic niche formation. Analysis of the composition within the sentinel lymph nodes 
for PD-L1 expression on macrophages could be useful in assessing the metastatic 
potential of that site. It is also important to consider the potential of targeting pathogenic 
exsomal release genes like YKT6. NSCLC patients with high YKT6 expression have 
previously been shown to have increased plasma concentrations of exosomes and 
worse survival outcomes 94. Within our own NSCLC patient cohort, YKT6 was shown to 
be increased in primary tumors and positively correlated with an immunosuppressive 
phenotype within the dLN. The development of new therapeutics aimed at these targets 
could decrease the prevalence of immunosuppressive PD-L1+ macrophages in a pre-
metastatic niche and lower the overall potential of primary tumor metastasis. 
In summary, we discover that TDE polarize tissue-resident macrophages towards an 
immunosuppressive phenotype in a pre-metastatic niche. This immunosuppressive “non-
classical M1” phenotype is characterized by: 1) increased de novo synthesis of PD-L1, 
2) expression of Arg-1 and iNOS and 3) inhibition of T cell effector functioning. Our
findings provide novel insight into how TDE orchestrate a pro-metastatic phenotype by 
reprogramming tissue resident macrophages. Pro-tumoral factors like IL-10, G-CSF, and 
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MCP-1 secreted from these “non-classical M1” macrophages further add to the 
downstream inflammatory milieu that ultimately characterizes a fully formed pre-
metastatic niche. Notably in the future, it would be interesting to investigate whether 
disruption to this pathway could provide benefit in decreasing primary tumor metastasis 
or could improve the efficacy of immunotherapies currently failing due to exosomal 
induced PD-L1 expression. 
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3. TUMOR DERIVED EXOSOMES DRIVE PD-L1 EXPRESSION THROUGH
METABOLIC REPROGRAMMING 
3.1 Introduction 
3.1.1 M1 versus M2 macrophage metabolism  
The macrophage compartment is a diverse and plastic lineage. While certain 
subsets of macrophages, like tissue resident, are seeded in early development, others 
are polarized towards a specific functionality by environmental factors43. As a 
consequence of these different polarization mechanisms, the resulting macrophages 
often have specific characteristics that are associated with each particular type. 
Currently, the widely accepted paradigm is that there are two overarching classes of 
macrophages: M1-like macrophages which are pro-inflammatory in nature can be 
polarized by Th1 related cytokines while M2-like macrophages are influenced by Th2 
related cytokines like IL-4 and are considered more immune dampening95. 
The idea of the M1 versus M2 macrophages activation spectrum originally 
came from experiments focused on the differential T lymphocyte responses to 
Leishmania major infection in resistant C57BL/6 versus susceptible BALB/c mice. T 
lymphocytes in C57BL/6 mice responded to the infection by producing large amounts 
of the macrophage activating cytokine, IFNγ. Consequently, macrophages in these 
mice had high expression of inducible nitric oxide synthase (iNOS) and generated 
large amount of nitric oxide (NO) to kill the pathogen. Conversely, macrophages from 
the BALB/c mice had increased expression of arginase and stimulated production of 
TGF-β rather than IFNγ from associated T cells. These seminal experiments 
established key identifying characteristics that are still used today to classify M1 
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versus M2 macrophages. Specifically, M1 macrophages are considered to express 
high levels of iNOS and produce inflammatory cytokines like TNFα and IL-1β whereas 
M2 macrophages have high arginine expression and secrete immune modulating 
cytokines like TGF-β, and IL-1056, 96. While there is only on class of M1 macrophages, 
M2 macrophages can be further broken down into M2a, M2b, M2c, and M2d, based 
on their polarization stimuli97. 
In addition to cytokine profile, one of the more common ways to distinguish 
macrophage subtype is through metabolic profiling. The dynamic changes in 
macrophage phenotype are also associated with characteristic signatures in cell 
metabolism. M1 macrophages mainly rely on glycolysis for energy production while 
M2 macrophages are more dependent on the citric acid cycle (TCA) and 
mitochondrial oxidative phosphorylation (Schematic 1) 98. Since glycolysis is one of 
the simplest ways to produce energy in the cell, it is logical that this is the preferential 
mechanism of energy production in inflammatory macrophages which are first 
responders in the context of injury or infection97. Overall, in glycolysis, two molecules 
of ATP are generated for each unit of glucose converted into pyruvate. Other 
intermediate molecules are also generated during this process that can also be used 
for amino acid and fatty acid synthesis.  
Following an immune response, infiltration of anti-inflammatory M2-like 
macrophages is necessary to prevent excess damage to host tissues. Therefore, their 
metabolic phenotype needs to mimic and support this function. M2-like macrophages 
mainly rely on increased expression of arginase to shuttle arginine into ornithine 
rather than NO97. Ornithine has been shown to increase cell growth and aid in wound 
healing. Additionally, other intermediates within the TCA cycle, like itaconate and α-
ketoglutarate, have also been shown to perpetuate anti-inflammatory properties99. 


















Schematic 1. Overview of glycolytic and oxidative metabolism. Generalized 
overview showing the different fates of glucose. HK1-hexokinase-1, LDH-lactate 




ATP for one unit of glucose, but the metabolic intermediates generated are also 
beneficial to M2 macrophages in functionally controlling inflammation.  
3.1.2 Warburg Metabolism 
In the context of cancer, TAMs are considered a subgroup of M2-like 
macrophages, specifically M2d97. They are polarized by TLR ligands, secrete 
immunosuppressive cytokines like IL-10, express characteristic surface markers of 
CD206, CD163, and like most M2’s, have increased expression of Arginase-1 and 
indoleamine 2,3-dioxygenase (IDO-1). The immunosuppressive “M2-like” phenotype 
of TAMs is often credited to promote tumor angiogenesis, growth, and metastasis100. 
Classically then, it was thought that TAMs metabolic signature would be similar to the 
other counterparts in the subgroup, namely oxidative phosphorylation. Isolation of 
macrophages from a variety of tumors did indeed show dependence on mitochondrial 
respiration and increased oxygen consumption101, 102, 103. However, more recent 
reports seemingly suggest that the TAM metabolic phenotype is closely linked to time 
and tumor staging104. 
Transcriptomic studies conducted on early tumors demonstrate a pronounced 
glycolytic phenotype in macrophages that display characteristic M2 associated 
markers such as Arg-1, CD206 and CD163105. Overtime, as the tumor 
microenvironment becomes more hypoxic as the diffusion gradient of oxygen 
decreases due to increasing tumor size, TAMs began to switch to a less glycolytic and 
more oxidative phenotype106. Macrophages isolated from pancreatic ductal 
adenocarcinoma (PDAC) lesions demonstrated marked increased in extracellular 
acidification rate (ECAR) and decreases in oxygen consumption107. Interestingly, 
these macrophages were shown to help tumor cells undergo EMT and extravasate 
through a mock endothelial lumen. Inhibition of glycolysis using 2-DG blunted the pro-
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metastatic capabilities of the TAMs. This phenomenon of preferentially using 
glycolysis despite normoxic conditions is called the Warburg Effect108. 
The Warburg effect was first described in the 1920’s by Otto Warburg and his 
colleagues who noticed that tumor cells were utilizing more moles of glucose than the 
surrounding tissue109. Today, this is the basis for Fluoro-deoxyglucose Positron 
Emission Tomography (FDG-PET) that is used clinically to image and visualize 
growing tumors in the body. There have been many different speculations as to why 
tumor cells would choose to forgo quantity of ATP over rate of ATP production 
including increased utilization of a limited resource, enhanced disruption to tissue 
architecture and immune cell evasion, and promotion of flux into biosynthetic 
pathways109. While these questions remain the topic of further investigation in the 
field, one fact regarding Warburg Metabolism is consistent, the production of the 
metabolic by-product lactate. 
3.1.3 Lactate 
Lactate is normally produced under anaerobic conditions such as during a 
strenuous workout regimen in which the oxygen demands of the muscles surpasses 
the oxygen concentration in the tissue resulting the generation of the lactate110. 
However, while the exact mechanism is unknown, cancer cells choose to convert the 
majority of their glucose into lactate despite both normoxic conditions and incurred 
deficit of ATP production. One proposed hypothesis is that aerobic glycolysis and 
lactate production is an immunological defense mechanism111. Glucose is an essential 
nutrient to immune cells while lactate is not. Therefore, by consuming the essential 
resource for localized immune cells, particularly lymphocytes, tumors are able to 
starve out and neutralize the immunological threat. Additionally, lactate has directly 
been shown to inhibit proliferation and effector function of cytotoxic T cells112, 113. 
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Acidification of the local microenvironment by lactate also results in decreased 
lymphocyte viability and functionality108.  
While lactate is detrimental to immune cells, multiple studies have shown 
lactate to be a beneficial metabolite to tumor cells. Lactate promotes tumor cell 
growth and expansion114, 115.  Additionally, while lactate kills off the cytotoxic 
lymphocytes, it is also capable of reprogramming infiltrating macrophages to a pro-
tumoral phenotype116. A recent seminal study determined that lactate is capable of 
inducing a novel epigenetic modification on macrophage histones called lactylation117. 
In the context of M1 polarizing stimuli, M1 macrophages generate copious amount of 
both intracellular and extracellular lactate. This pool of lactate results in lacytlation of 
exposed histone lysine residues triggering the “lactate clock”. Overtime, as lacytlation 
levels increase, homeostatic genes like Arg-1 are activated. These results support the 
claim that in the context of cancer, TAMs start as glycolytic Warburg like M1s but then 
overtime transition to the classical M2 phenotype.    
3.1.4 Summary and Findings 
The purpose of this study was to determine the mechanism by which TDE polarize 
tissue resident macrophages within a pre-metastatic site towards an immunosuppressive 
phenotype. Overall, with this study, we uncover a novel link between exosomes, 
metabolism, and glycolytic metabolism. Specifically, we show that TDE through NF-ĸB 
signaling, drive a highly glycolytic phenotype reminiscent of Warburg metabolism in 
stimulated macrophages. These cells are shunted down the glycolytic path by increases 
in nitric oxide which directly inhibit oxidative phosphorylation. As a consequence of 
increased glycolysis, there is a marked increase in secretion of lactate from these cells. 
We found that this increased pool of lactate feeds back on the cells and promotes PD-L1 
upregulation. Inhibition of glycolysis via 2-deoyxglucose or inhibition of lactate production 
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with oxamate, dramatically reduced the glycolytic capacity, and PD-L1 expression. A 
similar phenotype was seen with exosomes isolated from human NSCLC cell lines. 
Additionally, in the dLN of NSCLC patients, PD-L1 expression positively correlated with 
GLUT-1 expression on resident macrophages. Taken together, our findings support the 
idea that TDE drive primary tumor metastasis through NF-κB mediated reshaping of 
macrophage glycolytic metabolism resulting in an immunosuppressive phenotype 
characterized by increased PD-L1 expression and lactate secretion.  
3.2 MATERIALS AND METHODS 
3.2.1 Mice  
C57BL/6 mice were purchased from commercially available vendors. LysM-cre;HIF1-αfl/fl 
mice were generated by crossing LysMCre/wt and HIF-1α f/f mice both which were 
purchased from Jackson Laboratory (Bar Harbor, ME). LysMwt/wt x HIF-1αf/f mice were 
used as controls. LysM-cre;Raptorfl/fl and LysM-cre;Rictorfl/fl mice were generated in a 
similar manner. All animals were housed and treated in accordance with institutional 
guidelines and approved by the Institutional Animal Care and Use Committee at the 
University of Louisville, Louisville, KY.  
3.2.2 NF-ĸB Phosphoflow studies  
For intracellular phosphorylation studies, peritoneal macrophages were seeded in a 24 
well plate (0.5x106/well). Cells were then stimulated with sodium L-lactate 20mM for the 
indicated time. Cells were then harvested from the plate and pelleted by centrifugation. 
They were then stained for viability. Cells were washed, pelleted, and resuspended in 
100μl of 4% formaldehyde per 1 million cells and fixed for 15 minutes at room 
temperature. Cells were then washed with PBS. Ice cold methanol (2mL) was then 
added to the cells while gently vortexing to a make a final concentration of 90% 
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methanol. Cells were permeabilized on ice for 10 minutes. Cells were then washed in 
excess PBS twice to remove methanol. Primary phospho-NF-κB p65 (Ser536) (93H1) 
(1:1600) and F4/80-APC was then added and incubated at RT for 1 hour. Cells were 
then washed in PBS twice. 100μl (0.625:100) secondary donkey anti-rabbit IgG Alexa 
Fluor 555 (Biolegend) was added and incubated at RT for 30 minutes in the dark. 
Cells were washed with PBS and ran on the BD FACS Canto (BD Biosciences). 
3.2.3 NF-ĸB Confocal Translocation  
For NF-κB translocation studies, peritoneal macrophages were plated on a glass 
cover slip in a 24 well dish and stimulated with sodium L-lactate for the indicated time. 
Cells were then washed with PBS, permeabilized with 0.3% Triton 100x, and stained 
with primary antibody NF-κB p65 (D14E12) (1:100) overnight at 4°C, washed with PBC 
and stained with secondary donkey anti-rabbit IgG Alexa Fluor 555 (Biolegend) 
(1:100) for 1 hour at room temperature. Fluorescent images were obtained using a 
Nikon confocal microscope A1R with appropriate lasers.    
3.2.4. Quantitative PCR  
Total RNA was extracted using TRizol (Invitrogen) and isolated according to 
manufacturer’s instructions. cDNA was generated using the iScript cDNA Synthesis 
Kit (Bio-Rad). mRNA expression analysis was carried out using iQ SYBR Green (Bio-
Rad). RNA concentration was quantified using NanoDrop RNA 6000 nano-assays and 
analyzed using the CFX Connect PCR Machine (Bio-Rad). See Table S2 for the 
primer sequences.  
3.2.5 Seahorse Extracellular Flux Assay 
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An XF96e Analyzer (Agilent Technologies, Santa Clara, CA) was used to measure 
bioenergetic function in isolated peritoneal macrophages. Prior to the run, sorted 
peritoneal macrophages were plated at a concentration of 0.6x105cells/ well. Cells were 
stimulated with MLE-12 or LLC exosomes (40 μg/mL) overnight. For all bioenergetic 
measurements, the culture media was changed 1 h prior to the assay run to unbuffered 
Dulbecco’s Modified Eagle Medium (DMEM, pH 7.4) supplemented with 11 mM D-
Glucose (Sigma cat. G7528), 2 mM L-glutamine (Mediatech cat. 61-030-RM), and 100 
µM L-carnitine (Sigma cat. C0283). The final concentrations of oligomycin (port A), 
FCCP (port B), and antimycin A/rotenone (port C) were 2 μg/ml, 2.5 μM and 10 µM/1 
µM, respectively. Three basal OCR measurements were recorded prior to injection of 
oligomycin. After recording the oligomycin-sensitive OCR, FCCP-sensitive rates were 
recorded. Finally, antimycin A/rotenone was injected to inhibit electron flow through the 
electron transport system. As a secondary measurement, extracellular acidification rate 
(ECAR) was also recorded, and 2-deoxyglucose was injected at final concentration of 
250 μM (port D) to interrogate the contribution of glycolysis to ECAR. 
3.2.6 Mitochondria Staining 
Cells were washed with PBS and resuspended in pre-warmed 0.1% BSA solution. 
Following Fc blocking, cells were stained with Mitotracker Red (20nM) and 
MitoTracker Green (80nM) for 30 minutes at 37°C. Cells were then stained for surface 
markers. For DCFDA staining, 100μL of 40μM DCFDA (abcam) was added to 100μL 
of cells (1x106) and incubated in the dark at 37°C for 30 minutes. Cells were then 
washed with PBS and stained for flow cytometry like normal.  
3.2.7 In vitro metabolism assays 
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2-NBDG (100μM, BioVision) was added to peritoneal macrophages previously 
cultured in glucose free RPMI for 2 hours. The following concentrations of metabolic 
inhibitors or substrates were used for 16 hour cell culture: 2-deoxy-D-glucose (1mM, 
Sigma), Sodium oxamate (10mM, Sigma), SEITU (1mM-5mM, Cayman Chemical), 
Dimethyl-2-oxoglutarate (1mM-5mM, Sigma), Sodium-L-Lactate (20mM, Sigma). 
Levels of L-lactate in the supernatants were measured by L-Lactate Assay Kit I (Eton 
Bioscience, San Diego, CA) according to manufacturer’s instructions.  
3.2.8 In vivo 18FDG uptake experiment 
8-10 week old C57BL/6 mice were injected i.v. with LLC exosomes (10μg, in 100μl 
PBS) every 3 days for 2 weeks. Mice were fasted for 12 hours prior to intraperitoneal 
injection with 18FDG. One hour after injection, the mice were euthanized, lungs were 
harvested and measured on a Biodex AtomlabTM 500 for radioactivity. Lung tissue was 
enzymatically digested (collagenase (5g/L), Hyaluronidase(0.4g/L), DNAse I 
(0.15g/L)) for 20 minutes with rotation at 37°C. Following digestion, RBC’s were lysed 
using ACK. Cells were stained with primary Biotin anti-mouse CD19 
(Biolegend,115504), secondary Streptavidin MicroBeads (Miltenyl Biotec,130-048-
101), CD8a (Ly-2) MicroBeads (Miltenyl Biotec,130-049-401), CD4 (L3T4) (Miltenyl 
Biotec,130-049-201) for 15 minutes. Cells were then magnetically separated on an 
autoMACS Pro separator (Miltenyl Biotec) using the positive selection protocol. The 
negative fraction was then collected and read on a Biodex AtomlabTM 500 for 
radioactivity. Cells were then resuspended in Trizol and saved in the -80°C for RT-PCR. 
3.2.9 Human metabolism Studies-In vitro culture 
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Sorted CD14+ cells were pre-incubated with BAY-11-7082 (0.2μg/mL) for 1 hour prior 
to 16 hour stimulation with A549 exosomes. Metabolic assays were conducted using the 
same concentrations and procedures as the mouse protocols.  
 
3.2.10 Human NSCLC Samples   
Samples were obtained as approved by the University of Louisville Institutional 
Review Board. Draining LN were obtained from lung transplant donors during lung 
resection and from cancer patients during tumor resection and/or biopsy. Patient 
information was summarized in Table S1. Lymph node samples were analyzed via 
flow cytometry using Viability Dye-APC-Cy7, CD68-PercP, CD206-PE, PD-L1-Pe-Cy7, 
and GLUT-1-primary (R&D, Clone 202915), secondary (R&D,α-mouse IgG-APC).   
 
3.3.1 TDE stimulation augments glycolytic phenotype in macrophages  
Macrophages can undergo polarized activation depending on different environmental 
cues99. The binary M1/M2 macrophage paradigm previously proposed considers M1 
macrophages to be pro-inflammatory, relying on glycolytic metabolism, while M2 are pro-
tumor, oxidative phosphorylation dependent 98. This dichotomy is now being challenged 
by the idea of an overlapping macrophage spectrum with cells capable of exhibiting both 
anti-tumoral and pro-tumoral characteristics depending on environmental context 96. 
Nevertheless, macrophage phenotype and polarization are closely associated with 
metabolic reprogramming. To first explore if metabolic alterations drive TDE-mediated 
macrophage polarization, glucose-deprived macrophages were co-cultured with 2-NBDG 
to assay glucose consumption. TDE-stimulated macrophages had significantly increased 
glucose uptake over control macrophages (Figure 16A). To determine if glucose 
metabolism was directly impacting the PD-L1 expression, peritoneal macrophages were 
cultured with 2-deoxyglucose (2-DG) with or without TDE treatment. 2-DG mediated 
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disruption to glycolytic metabolism significantly downregulated PD-L1 expression 
following TDE stimulation suggesting a role for glycolysis in driving PD-L1 expression 
(Figure 16B). Further analysis of metabolic enzymes showed increases in glucose 
transporter-1 (GLUT-1), hypoxia inducible factor-1α (HIF1-α), and lactose 
dehydrogenase A (LDHA) expression (Figure 16C).  Pyruvate dehydrogenase kinase 1 
(PDK1), inhibitor of the pyruvate dehydrogenase complex was also increased but in both 















































































































Figure 16. Metabolic phenotyping in TDE stimulated macrophages. (A) Peritoneal macrophages 
were pre-cultured in glucose depleted RPMI-1640 for 2 hours prior addition of 100μM 2-NBDG for 16 
hours. Representative histograms and summarized data are shown. n=3. *p<0.05 (unpaired student’s 
t test). (B) Peritoneal macrophages were cultured with or without LLC exosome (40μg/mL) in the 
presence or absence of 1mM 2-DG for 16 hours. PD-L1 expression was determined by flow 
cytometry. Representative histogram and summarized data are shown. n=3. (C) Peritoneal 
macrophages were stimulated with MLE-12 or LLC exosomes for 6 hours prior to quantification of 
glucose transporter-1 (GLUT-1), Hypoxia inducible factor-1α (HIF-1α), lactate dehydrogenase 
(LDHA), pyruvate dehydrogenase kinase 1 (PDK1), Hexokinase-1 (HK-1), and Isocitrate 
dehydrogenase-1 (IDH1), by RT-PCR. Data normalized to control expression level. n=3 mice per 
group. The data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (one-way 




































dehydrogenase-1 (IDH1) demonstrated no considerable differences in TDE-stimulated 
macrophages compared to control. 
Increased glucose uptake coupled to increased GLUT-1, HIF-1α, and LDHA expression 
suggest that TDE stimulated macrophages favor a highly glycolytic metabolic profile 
despite being in normoxic conditions. To confirm this hypothesis, we performed a 
Seahorse assay which measures both the extracellular acidification rate (ECAR) and 
oxygen consumption rate (OCR) in stimulated cells. As shown in Figure 17A, LLC 
exosome stimulated macrophages had an increased ECAR as compared to the controls. 
Interestingly, as shown in the OCR, the LLC exosome-stimulated macrophages were 
unresponsive to mitochondrial inhibitors, oligomycin and FCCP. This effect was not due 
to an excessive TDE treatment (Figure 17B). The bioenergetic profile showed a dramatic 
decrease in ATP-linked energy production in the TDE group, indicating a defect in 
mitochondrial respiration (Figure 17C). We evaluated the mitochondrial status of TDE-
stimulated macrophages using Mitotracker Green and Mitotracker Red staining that can 
distinguish between respiring mitochondria (MitoTracker Red+) and dysfunctional 
mitochondria (MitoTracker Green+/high, MitoTracker Red+/low) 118. Contrary to the media 
alone and MLE-12 exosome controls, LLC exosome-stimulated macrophages had a 
decreased proportion of solely Mitotracker Green+ cells and an increased number of 
Mitotracker Red+ cells (Figure 17D), indicating more respiring mitochondria.  
3.3.2 TDE inhibit oxidative phosphorylation via nitric oxide 
The bioenergetic profile also showed a high level of non-mitochondrial oxygen 
consumption in the TDE treated macrophages signifying another mechanism outside of 
mitochondrial ATP generation was utilizing the oxygen (Figure 17C). DCFDA staining 
showed TDE-stimulated macrophages generated less reactive oxygen species (ROS)  
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Figure 17. Glycolytic Phenotype in TDE stimulated macrophages. (A) ECAR (left) and 
OCR (right) of F4/80+ peritoneal macrophages were sorted from peritoneal lavage and seeded 
in Seahorse XF-96 cell culture microplates (0.6x105 cells/well). The cells were then pre-treated 
with MLE-12 or LLC exosomes (40μg/mL) for 16 hours, followed by sequential treatment with 
Oligomycin, FCCP, and antimycin A plus rotenone. Data are representative for n=4 
independent experiments. B) F4/80+ peritoneal macrophages were sorted and seeded in 
Seahorse XF-96 cell culture microplates (0.6x105 cells/well). The cells were then pre-treated 
with indicated concentrations of MLE-12 or LLC exosomes for 16 hours, followed by sequential 
treatment with Oligomycin, FCCP, and antimycin A plus rotenone. Data are representative for 
n=2 independent experiments (C) OCR Bioenergetic profiling showing relative values of 
parameters for representative Seahorse assay. (D) Peritoneal macrophages stimulated with 
control or TDE exosomes (40μg/mL) for 16 hours were stained with MitoTracker Red (20nM) 
and MitoTracker Green (80nM). Cells were assayed for mitochondrial functionality via flow 
cytometry. Representative flow plots and summarized data are shown. The data are shown as 






than the two control groups eliminating this as the potential source of oxygen 
consumption (Figure 18A). Another molecule often found within the tumor 
microenvironment that utilizes oxygen is nitric oxide (NO) 119. In addition to consuming 
free oxygen, NO can inhibit the electron transport chain via interfering with proper 
functioning of complexes III and IV within actively respiring mitochondria (Figure 18B)120. 
To test if NO mediated mitochondrial inhibition was occurring, we measured intracellular 
NOS2 expression following LLC exosome stimulation and indeed found increased 
expression (Figure 18C), which agrees with the previously shown mRNA iNOS data 
(Figure 5C). Addition of the NOS2 inhibitor, S-ethylisothiourea hydrobromide (SEITU) 
completely rescued the oxidative respiration capacity of the macrophages (Figure 18D). 
The bioenergetic profile demonstrated properly restored ATP synthesis in a dose 
dependent manner, indicating that NO is indeed responsible for inhibiting oxidative 
respiration (Figure 18E). Furthermore, stimulation of peritoneal macrophages with TDE 
in the presence of SEITU decreased PD-L1 expression suggesting that the PD-L1 is 
directly tied to glycolytic and not oxidative metabolism (Figure 18F). NOS2 expression in 
TDE stimulated macrophages was dependent on MyD88 signaling (Figure 18G) but 
independent of HIF1-α (Figure 18H) indicating that NOS2 and HIF-1α influence 
glycolysis through two separate mechanisms.  
3.3.3 HIF-1α is downstream of NF-κB in the TDE signaling cascade 
Further investigation into HIF-1α’s role in TDE metabolic reprogramming revealed 
that deficiency in HIF-1α results in decreased GLUT-1 expression and a marginal 
decrease in PD-L1 expression following TDE stimulation (Figure 19A). TDE stimulation 
in MyD88-/- macrophages dramatically decreased both HIF-1α and GLUT-1 expression 
indicating that these factors are indeed downstream of TLR2 signaling and are mediated 
by exosome ligation (Figure 19B). Interestingly, inhibition of NF-κB via BAY also 
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decreased HIF-1α expression indicating HIF-1α activation lies downstream of NF-κB 
(Figure 19C). Collectively, these data demonstrate that TDE polarize macrophages to 
increase PD-L1 expression through metabolic reprogramming. Specifically, NF-ĸB is the 
master transcription factor that activates HIF-1α/GLUT-1 to bring more glucose into 
macrophages and NOS2/NO to inhibit mitochondrial oxidative phosphorylation shunting 
pyruvate into lactate. Stimulation with oxidative metabolite, α-ketoglutarate, completely 
abolished PD-L1 expression in TDE stimulated macrophages (Figure 19D), further 
strengthening the causative relationship between glycolysis and PD-L1 expression.  
 
3.3.4 Glycolytic metabolism fuels lactate production and PD-L1 expression 
One of the classic hallmarks of Warburg metabolism is not only glycolysis in 
normoxic conditions but also the shunting of pyruvate away from Acetyl-CoA and into 
lactate. Having demonstrated that TDE polarize macrophages towards a highly glycolytic 
phenotype reminiscent of Warburg metabolism, we hypothesized that lactate production 
may be enhanced in TDE-treated macrophages and lactate may act as the critical 
metabolite to induce PD-L1 expression. To test these hypotheses, we first measured the 
concentration of lactate in the supernatant from macrophage culture. As compared to the 
other controls, stimulation with TDE augmented lactate secretion (Figure 20A). 
Increasing numbers of macrophages expectedly increased the concentration of secreted 
lactate following TDE stimulation (Figure 20B). The increased lactate was a result of 
exosomal ligation and signaling through the MyD-88 pathway (Figure 20C). Inhibition of 
NF-κB also decreased lactate production following TDE stimulation (Figure 20D). HIF-1α 
deficiency notably abrogated the amount of secreted lactate but not back to baseline 
providing further evidence for the contribution of the NOS2 pathway to lactate secretion 
(Figure 20E). In addition, the mRNA expression of lactate exporter, monocarboxylate 
75 
transporter-4 (MCT4) was increased, which may account for the increased ability of 
these cells to secrete lactate into the supernatant (Figure 20F). We next sought to 
determine if lactate was the ultimate downstream metabolite of augmented glycolysis 
that was responsible for driving increased PD-L1 expression. Stimulation of peritoneal 
macrophages with lactate did increase PD-L1 expression (Figure 21A). Furthermore, 
Phosflow assay revealed that lactate induced phosphorylation of NF-ĸBp65 at 15 and 
30-minutes (Figure 21B). These results were verified using a confocal microscopy that 
demonstrated peak NF-kBp65 translocation into the nucleus at 30 minutes following 
lactate stimulation and regression to the cytoplasm by one hour (Figure 21C). Flow 
cytometric analysis further confirmed lactate indeed induced PD-L1 expression in an NF-
ĸB-dependent manner (Figure 21D). RT-PCR results recapitulated this finding (Figure 
21E). RT-PCR analysis also showed an increase in lactate importer monocarboxylate 
transporter-1 (MCT-1) following TDE stimulation suggesting extracellular as well as 
intracellular lactate can be driving this phenotype (Figure 21F).  
Having shown that TDE stimulation increases the secretion of lactate and that lactate 
is indeed capable of upregulating PD-L1, we next validated this conclusion by inhibiting 
lactate synthesis following TDE stimulation using the LDHA inhibitor oxamate (OXA). As 
shown in Figure 21G, stimulation of macrophages with TDE in the presence of OXA 
decreased the expression of PD-L1 thus supporting our hypothesis that lactate is indeed 
the downstream effector metabolite that can drive autocrine PD-L1 expression through 
NF-κB activation. Together, these data show a novel role for lactate in driving PD-L1 
expression. Specifically, we propose in our model that TDE signaling activates NF-κB 
and its downstream effectors NOS2 and HIF-1α, to augment glycolytic metabolism and 
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Figure 18. Nitric Oxide drives glycolytic phenotype. (A) DCFDA/Reactive Oxygen species 
content (20μM) analyzed by flow cytometry in macrophages stimulated with control or TDE 
(40μg/mL) for 16 hours. Representative histograms and summarized data are shown. (n=3). 
(B) Schematic diagram depicting the electron transport chain (ETC) and NO mediated 
inhibition. (C). Intracellular NOS2 expression in peritoneal macrophages stimulated with MLE-
12 or LLC exosomes for 16 hours. Representative histogram and summarized data are shown 
(n=3). (D) F4/80+ peritoneal macrophages were sorted and seeded in a Seahorse XF-96 cell 
culture microplate (0.6x105 cells/well), stimulated with or without LLC exosomes (40μg/mL) for 
16 hours in the presence of 2mM or 4mM SEITU and real-time OCR was determined at basal 
level and in response to sequential treatments of oligomycin, FCCP, antimycina/rotenone, and 
2-DG. Data are representative of two independent experiments with similar results. (E) OCR 
bioenergetic profiling showing relative values of parameters for representative Seahorse 
Assay where peritoneal macrophages were treated with NOS2 inhibitor, SEITU. (F) 
Expression of PD-L1 in peritoneal macrophages treated with TDE with or without SEITU. 
(4mM) for 16 hours. Representative histogram and summarized MFI data are shown. n=3. 
***p<0.001 (unpaired student’s t test). (G) Intracellular NOS2 expression of WT or MyD88-/- 
peritoneal macrophages stimulated with LLC exosomes (40μg/mL) for 16 hours assessed by 
flow cytometry. n=4 mice per group. (H) Intracellular NOS2 expression in HIF-1αf/f and LysM-
cre;HIF-1αf/f peritoneal macrophages following 16 hour stimulation with LLC exosomes. n=3 
mice per HIF-1αf/f control group; n=4 mice per LysM-cre;HIF-1αf/f group. The data are shown 






















































































































Figure 19. The role of HIF-1α in the TDE signaling cascade (A) RT-PCR analysis of GLUT-
1 mRNA (left) and PD-L1 surface (right) expression in HIF-1αfl/fl and LysM-cre; HIF-1αfl/fl 
peritoneal macrophages treated for 6 hours and 16 hours, respectively, with LLC exosomes (B) 
The mRNA expression levels of HIF-1α and GLUT-1 expression in wild type or MyD88-/- 
peritoneal macrophages stimulated with LLC exosomes (40μg/mL) for 6 hours. n=4 mice per 
group. (C) The mRNA expression levels of HIF-1α in peritoneal macrophages pre-treated with 
the NF-κB inhibitor, BAY-11-7082 (0.2μg/mL) for 1 hour prior to 6 hour LLC exo. stimulation. 
n=3. (D) PD-L1 expression in peritoneal macrophages co-cultured with LLC exosomes and 
dimethyl-α-Ketoglutarate for 16 hours n=3. The data are shown as mean ± SEM. *p<0.05, 







































































































































Figure 20. Glycolytic metabolism fuels lactate production (A) Supernatants from 
peritoneal macrophages treated with MLE-12 or LLC exosomes (40μg/mL) for 16 hours were 
collected. Levels of L-lactate in the supernatants were determined by lactate assay kit. n=3. 
(B) Concentration of L-lactate in the supernatant of increasing numbers of peritoneal 
macrophages treated with LLC exosomes. n= 3 mice per group. (C) Level of L-lactate in the 
supernatant of WT or MyD88-/- macrophages stimulated with TDE exosomes for 16 hours. 
n=3. (D) L-lactate levels in the supernatant of peritoneal macrophages pre-treated with 
0.2μg/mL BAY-11-7082 for 1 hour prior to 16 hour stimulated with TDE. n=3. (E) 
Supernatants from HIF-1αf/f and LysM-cre;HIF-1αf/f peritoneal macrophages treated with LLC 
exosomes (16 hours) were collected and L-lactate concentration was determined. (F) The 
mRNA expression levels of monocarboxylate transporter-4 (MCT-4) on peritoneal 
macrophages treated with TDE for 6 hours. n=3. Expression levels were normalized to the 
control. *p<0.05 (unpaired student’s t test). The data are shown as mean ± SEM. *p<0.05, 
**p<0.01, ***p<0.00, ****p<0.0001 (one-way ANOVA with multiple comparisons). 















































































































































  Figure 21. Lactate upregulates PD-L1 in an NF-ĸB dependent manner (A) 
Summarized PD-L1 expression in peritoneal macrophages stimulated with 20mM L-
lactate for 16 hours in glucose depleted RPMI-1640 culture medium (n=3). *p<0.05 
(unpaired student’s t test). (B) Intracellular phosphorylated NF-κBp65 expression (pNF-
κBp65) expression assessed by flow cytometry following stimulation with L-Lactate 
(20mM) for indicated time. Representative histograms and summary MFI data are shown 
(n=3). (C) Confocal translocation assay demonstrating increased co-localization of NF-
κBp65 to the nucleus following 30 minutes stimulation with 20mM L-lactate. Scale bar = 
10μm. (D) PD-L1 expression in peritoneal macrophages pretreated for 1 hour with BAY 
prior to 16 hour stimulation with 20mM sodium L-lactate. Representative histogram and 
summarized MFI data are shown. n=3. (E) mRNA levels of PD-L1 in peritoneal 
macrophages pretreated for 1 hour with BAY prior to 6 hour stimulation with 20mM 
sodium L-lactate.(F) mRNA expression level of monocarboxylate transporter-1 (MCT-1) in 
peritoneal macrophages treated with LLC exosomes for 6 hours. Data normalized to 
control. n=3. *p<0.05 (unpaired student’s t test). (G) PD-L1 expression in peritoneal 
macrophages treated with TDE for 16 hours with or without the presence of Oxamate 
(10mM). Representative histograms and summarized data are shown. n=3. (H) Schema 
depicting TDE-induced PD-L1 expression via direct NF-κB transcription and NF-κB 
mediated glycolytic metabolism. The data are shown as mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001 (one-way ANOVA with multiple comparisons). 
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feedback on NF-κB, further increasing PD-L1 expression and maintaining the 
enhanced glycolytic phenotype. 
3.3.5 In vivo assessment of TDE induced glycolytic and PD-L1 phenotype 
Our in vitro results indicate that TDE drive glycolytic metabolism in macrophages 
through NF-κB mediated induction of HIF-1α and NOS2. Next, we wanted to confirm that 
tissue resident macrophages in vivo also display this augmented glycolytic phenotype 
following TDE stimulation. To achieve this, we injected C57BL/6 mice with LLC or MLE-
12 exosomes intravenously every 3 days for 2 weeks (Figure 22A). The day after the 
final treatment, mice were intraperitoneally injected with 18F-fluorodeoxyglucose (FDG). 
Clinically, 18F-fluorodeoxyglucose positron emission tomography/ computed tomography 
is an essential imaging modality for NSCLC lesions with increased uptake often 
correlating with increased tumor PD-L1 expression121.  In our study, one hour after 
injection of 18FDG, the mice were euthanized and whole lung radioactivity was measured 
which demonstrated no significant difference between the two treatment groups (Figure 
22B). However, the macrophage enriched population isolated from the lungs of TDE 
treated mice had a marked increase in 18FDG uptake as compared to the control group 
(Figure 22C). Furthermore, the macrophage enriched population from the TDE group 
also demonstrated increased expression of PD-L1, HIF-1α, and MCT-4, as compared to 
the control group (Figure 22D). Taken together, these results validate our in vitro 
findings that TDE stimulation results in enhanced glycolytic metabolic reprogramming of 
tissue resident macrophages which drives upregulation of PD-L1.  
3.3.6 Human TDE induced metabolic phenotype 
Next, we wanted to determine if metabolic alterations similarly influenced human PD-
L1 expression on CD14+ macrophages. Inhibition of glycolysis via 2-DG significantly 
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decreased PD-L1 expression following A549 exosome treatment (Figure 23A). Flow 
cytometric analysis of GLUT-1 showed increased expression following TDE stimulation 
compared to the controls (Figure 23B). Investigation into the lactate compartment of 
these cells reveled, as expected, a TLR2 dependent increase in lactate secretion into 
the supernatant upon TDE stimulation (Figure 23C). Likewise, stimulation with 
exogenous lactate increased PD-L1 through NF-κB (Figure 23D). Overall, these data 
suggest that human TDE metabolically reprogram CD14+ monocytes via the same 
metabolic mechanism elucidated in mouse models.    
Understanding that human TDE also influence the metabolic phenotype of 
macrophages, we wanted to correlate PD-L1 expression to metabolism in a human pre-
metastatic niche. We split the CD68+ macrophages within the dlN into two groups, 
CD206hiPD-L1hi and CD206loPD-L1lo, and then measured GLUT-1 expression using flow 
cytometry. The CD206hiPD-L1hi group demonstrated an increased GLUT-1 expression 
compared to the CD206loPD-L1lo (Figure 23E). Strikingly, given the small sample size, 
the GLUT-1 expression on the CD68+ cells positively and significantly correlated with 
their CD206/PD-L1 expression (Figure 23F). Taken together, these results suggest that 
despite the negative LN staging, dynamic changes in the metabolism of local myeloid 























































































































Figure 22. In vivo assessment of glucose uptake in TDE primed macrophages (A) 
Schematic for experimental design (B-D). (B) Radioactivity measured by Biodex 
AtomlabTM 500 following intraperitoneal injection of 18fluordeoxyglucose (18FDG) in the lungs 
of C57BL/6 mice treated i.v. every 3 days for 2 weeks with control MLE-12 exo. or LLC exo 
(10μg/mouse). n=4 per MLE-12 exo group; n=9 per LLC exo group. (C) 18FDG uptake in the 
macrophage population enriched via magnetic cell isolation from the lungs of MLE-12 exo or 
LLC exo treated mice. **p<0.01 via Mann-Whitney U test. (D) mRNA expression of PD-L1, 
HIF-1α, and MCT-4 in the macrophage enriched population in MLE-12 exo versus LLC Exo 
treated mice. n=3. Representative dot plots and summarized data are shown. The data are 



















































Figure 23. Human TDE drive PD-L1 expression through metabolic reprogramming. (A) 
Sorted CD14+ cells were stimulated with A549 exosome with or without 2-DG (1mM) for 16 
hours. n=3. (B) GLUT-1 expression measured by flow cytometry following HBEC or A549 
exosome stimulation for 16 hours. n=4. (C) Levels of L-lactate in the supernatants of sorted 
CD14+ cells pre-treated with 0.2μg/mL BAY for 1 hour prior to A549 exosome stimulation. (D) 
PD-L1 expression in CD14+ cells following 16 hour stimulation with lactate (20mM) with or 
without 1 hour pretreatment with BAY-11-7082. (E) GLUT-1 expression in CD206hiPD-L1hi 
versus CD206loPD-L1lo CD68+ macrophages. ***p<0.001 (unpaired student’s t test). (F) 
Pearson correlation between CD206/PD-L1 and GLUT-1 expression in CD68+ macrophages 
in NSCLC dLN. The data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 (one-way 






































































One of the defining characteristics of a pre-metastatic niche is immunosuppression. 
Without dampening or neutralization of cytotoxic immune responses, circulating tumors 
cells would not be able to engraft and grow in a secondary site following extravasation 
from the blood vessel.  While many pro-tumoral cell types have been identified within the 
pre-metastatic niche, the most well characterized is the macrophage. Due to their 
inherent plasticity, these cells have been shown to alter their metabolic phenotype and 
functioning towards a tumor promoting phenotype when placed in proximity to malignant 
cells.  
In macrophages biology, metabolic phenotype is closely tied to function. Macrophage 
classification is often associated with particular metabolic signatures. In cancer, 
macrophages are often classified as the tumor-promoting, “M2” subtype, indicated by 
their increased Arg-1 expression and reliance on mitochondrial oxidative metabolism. 
This paradigm was recently challenged when human monocytes were cultured with 
conditioned media from pancreatic ductal adenocarcinoma (PDAC) and demonstrated a 
pronounced glycolytic signature reminiscent of the Warburg effect 107. The increased rate 
of glycolysis in tumor cells ultimately drives an increased production of lactate, a pro-
tumoral metabolite capable of increasing KRAS driven tumor growth and reducing anti-
tumor T cell expansion 112, 122. Recently, intracellular lactate was found to induce a new 
type of epigenetic modification called lactylation that drove M2 gene expression within a 
classic M1 polarized macrophage 117. Here, we demonstrate another novel mechanism 
by which macrophages acquire a “non-classical M1” phenotype characterized by PD-L1 
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mediated immunosuppression and enhanced glycolytic metabolism. While lactate has 
previously been associated with an immunosuppressive TAM phenotype (42), we 
discover, for the first time, a role for lactate in driving PD-L1 expression in an autocrine 
manner in “non-classical M1” macrophages. Any inhibitory perturbations to our proposed 
glycolytic pathway significantly decreased PD-L1 expression due to blunted lactate 
production. Furthermore, addition of an oxidative metabolite like α-ketoglutarate 
completely blocked TDE driven PD-L1 upregulation again strengthening the important 
relationship between glycolysis, lactate and PD-L1.  
We demonstrate that NF-kB pathway directly regulates this “non-classical M1” 
phenotype. In addition to directly facilitating PD-L1 expression by binding to the promoter 
81, we report here a novel mechanism by which NF-κB regulates PD-L1 expression 
through metabolic alterations. Following signaling from TLR2/MyD88 TDE ligation, NF-
κB activates two distinct pathways that independently augment glycolysis. First, HIF-1α 
activation leads to an increased expression of GLUT-1 resulting in a higher rate of influx 
of glucose into macrophages. Secondly, activated NOS2 increases the production of NO 
which in turn inhibits complexes III and IV of the electron transport chain thus effectively 
shunting pyruvate into lactate. Therefore, akin to Warburg metabolism, TDE stimulated 
macrophages are preferentially using glycolysis in normoxic conditions because the 
mitochondrial oxidative phosphorylation pathway has effectively been eliminated by NO. 
Inhibition of NO by SEITU completely restored normal oxidative metabolism further 
supporting this notion. The enhanced glycolysis eventually leads to more lactate 
production and subsequent PD-L1 expression on macrophages. We demonstrate that 
lactate directly activates NF-kB leading to PD-L1 expression on macrophages. 
Interestingly, previous studies have shown that lactate stimulates NF-kB activation in 
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endothelial cells 123 and cancer-associated fibroblasts 124 to drive tumor angiogenesis 
and adaptive resistance to targeted therapies.  
Clinically, the concept of Warburg metabolism seen in tumors lead to the utilization of 
FDG-PET scans to visualize growing tumors within the body. We aimed to use a similar 
concept in our studies to demonstrate that macrophages using Warburg metabolism 
display an increased capacity for glucose uptake. Results from our in vivo studies 
demonstrate the indeed macrophages within the lungs of mice primed with TDE have 
increased glucose uptake compared to control. The macrophages with increased FDG 
uptake also had increased expression of PD-L1, HIF-1α, and MCT4. Going forward, 
these data seemingly call into question the role macrophages within tumors play in FDG-
PET glucose uptake. Could these cells be the main consumers of FDG-glucose rather 
than the tumor cells? Additionally, could glucose tracing be a viable way to identify a 
potential site of metastasis? The results of our study suggest that within the dLN of 
NSCLC patients, CD68+ macrophages that have increased co-expression of PD-L1 and 
GLUT-1. While this is just correlative data, it does suggest that macrophages within a 
pre-metastatic site could potentially be identified using a form of labeled glucose tracing.  
Overall, our findings provide mechanistic insight as to how TDE polarize tissue 
resident macrophages towards a PD-L1+ immunosuppressive phenotype through 
metabolic reprogramming. Specifically, we found that TDE stimulation augments 
glycolytic metabolism in both mice and humans through NF-κB mediated conversion of 
pyruvate into lactate with subsequent lactate driven PD-L1 expression. Additionally, data 
from our own NSCLC patient cohort demonstrated a notable correlation between PD-L1 
and GLUT-1 expression within a pre-metastatic site. Therefore, going forward, it would 
be interesting to further explore whether inhibiting immunosuppressive metabolites like 
89 
lactate could increase the efficacy of immune checkpoint therapy and whether increased 
glucose uptake could be used clinically as a marker for pre-metastatic niche formation.  
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4. CONCLUDING REMARKS AND FUTURE DIRECTIONS
The overall aim of this study was to determine if tumor derived exosomes contribute 
to the earliest precipitating events in pre-metastatic niche formation leading to the 
characteristic overt immunosuppressive phenotype. Our findings suggest that indeed 
TDE do polarize tissue resident macrophages towards a “non-classical M1” 
immunosuppressive phenotype characterized by increased PD-L1 expression and 
lactate secretion. Given these results, we probed further to identify the mechanism that 
drove this phenotype. Since metabolism is often linked with macrophage function, we 
hypothesized that TDE simulation alters macrophage metabolism. While we originally 
anticipated TDE to skew metabolism towards an M2-like phenotype due to the apparent 
similarities in Arginase-1 and IL-10 expression, pivotal experiments demonstrated a 
distinct glycolytic, M1-like phenotype. Overall, we found that NF-κB acts as a master 
regulator of NOS2 and HIF-1α that causes shunting of glucose into lactate via NO 
mediated inhibition of oxidative phosphorylation. The increased secretion of lactate 
feeds back and drives further PD-L1 expression. Additionally, using a small cohort of 
NSCLC patients, we found that even within metastasis negative dLNs, macrophages 
already demonstrate increased PD-L1 and CD206 expression. Correlation with GLUT-1 
seemingly suggests to implicate increased glycolysis as one proposed mechanism 
driving the PD-L1 expression. Patients that had the highest PD-L1 expression also had 
an increase in exosomal release genes, YKT6 and TSG101.  
There are two important ancillary questions raised by the findings in our study. First, 
given these data, how does TDE-induced PD-L1 contribute to immune checkpoint 
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therapy failure? Specifically, we found exosomes drive increased PD-L1 expression on 
macrophages, does this excess source of PD-L1 sequester anti-PD-L1 antibody allowing 
tumor derived PD-L1 to inhibit effector T cell function? Would inhibition of exosome 
release from primary tumors using targeted siRNA to YKT6 decrease macrophage PD-
L1 expression and rescue immune checkpoint therapy? Would it decrease the rate of 
primary tumor metastasis? Additionally, based on our study, deeper inquiry is needed 
into the role lactate plays in antagonizing immune checkpoint therapy. Do T cells that 
have escaped PD-L1 mediated inhibition ultimately fail due to excessive lactate 
production within the tumor or pre-metastatic environment? Further investigation into 
strategies that can neutralize these factors is important to improving overall survival 
rates for patients treated with immune checkpoint therapies.  
Secondly, our study indicates that macrophages like tumor cells, have an increased 
glycolytic capacity that can be identified via glucose tracing. Current protocols for 
screening axillary draining lymph nodes during breast cancer surgery involves utilization 
of a blue colloid dye or a radiocolloid isotope tracer. Lymph nodes that are either “hot” 
and/or “blue” are considered to be the sentinel lymph node from the tumor and 
removed125. If the sentinel lymph node contains metastatic tumor cells, additional lymph 
nodes are removed. However, while this process called sentinel lymph node biopsy and 
axillary lymph node dissection has improved outcomes for patients by decreasing risk of 
metastasis, it often results in the serious complication of lymphedema. In one study, hot 
sentinel lymph nodes were identified and excised in 97% of patients125. However, only 
20% were actually malignant. Therefore, there is a clinical need for improved screening 
techniques with increased sensitivity and specificity to correctly identify metastatic nodes 
or those with a high metastatic potential versus healthy tissue. Given the results of this 
study, I believe that adopting a modified form of localized glucose tracing could be useful 
in identifying, in real time, the metastatic potential of a lymph node.  
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In conclusion, this study expands upon the current knowledge in the field regarding 
primary tumor metastasis. It also unveils a novel connection between exosomes, 
metabolism, and metastasis that could serve as a future target in the field of 
immunotherapy.  
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